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ABSTRACT 
v 
ABSTRACT 
Good oral health has a major influence on the general quality of life and well-being. Several 
chronic and systemic diseases have been attributed to poor oral health. With the increasing 
incidence of oral diseases, the global need for alterative prevention and treatment methods 
and safe, effective, and economical products has expanded. There are many studies showed 
that Streptococcus mutans has been implicated as major etiological agent of dental caries. 
South African has very rich natural flora especially Cape region. Several South African 
medicinal plants have been used since immemorial time for treatment of different human 
pathologies including dental problems. The antibacterial activities of plants extracts have 
been recognized and documented scientifically during the last few decades. In this project we 
aimed at the screening of 31 South African plants randomly collected from Cape region for 
their antibacterial activity against Streptococcus mutans initially at two concentrations (500 
and 100 µg/ml).MIC’s and MBC’s were determined for the active plant extracts, as well as 
the qualitative studies of the effect of the active extracts on the biofilm formation. The best or 
the most active safe plant (Psoralea fruticans) was submitted to chromatographic separation 
to isolate the bioactive compounds which could be responsible for such activity. 
Identification of the pure active compounds was carried out using different spectroscopic 
techniques. Finally the biological evaluation of the isolated pure compounds was measured 
against S. mutans and also the cytotoxicity studies in-vitro against normal cells lines was 
carried out. 
Keywords: Oral care, Streptococcus mutans, Cape flora, plant extracts, Psoralea fruticans, 
antibacterial activity, inhibition of biofilm formation, cytotoxicity, biological screening 
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CHAPTER 1 
INTRODUCTION AND LITERATURE REVIEW 
1.1 Introduction 
Oral diseases are major health problems with tooth decay and gum disease representing a 
serious infectious disease that require global attention. Oral health affects the general quality 
of life and is associated with poor oral health, chronic diseases and systemic diseases. Many 
of the more than 750 species of bacteria that live in the mouth cavity can cause a number of 
oral diseases. The development of dental caries involve acidogenic bacteria and acid-tolerant 
Gram-positive bacteria (Streptococcus mutans, Lactobacilli and Actinomycetes). Periodontal 
diseases have also been linked to anaerobic Gram-negative bacteria (Porphyromonas 
gingivalis, Actinobacillus, Prevotella and Fusobacterium). Due to the occurrence of oral 
disease, increasing resistance of bacteria to antibiotics, the negative or side effects of some 
antibacterial agents currently used in dental medicine and financial considerations in 
developing countries, there is a need for alternative prevention and treatment options that are 
safe, efficacious and cost-effective. Commercially available products contain different 
synthetic chemicals that alter the oral bacterial populations (microbiome or microbiota) and 
have undesirable side effects such as vomiting, diarrhoea and staining of teeth. Consequently, 
the search for alternative products continues and natural phytochemicals isolated from plants 
used as traditional medicines are considered good alternatives.1  
1.2 Oral Diseases 
Periodontal diseases and tooth decay, as mentioned before, are the most prominent global 
oral health problems, although some conditions such as oral cancers and oral tissue lesions 
are also the cause of considerable health concerns.2 Despite the popular progress in the 
overall health. 
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status, including oral and dental health, of populations living in industrialized countries, the 
spread of dental caries among children at schools is estimated at more than 90%, but also 
affects the majority of functions of craniofacial complex parts beyond adult life. There is 
considerable evidence linking poor oral health to chronic diseases, for instance, there is a 
significant association between rugged periodontal disease and diabetes.2 Several lines of 
evidence suggest a link between poor oral health and systemic diseases, like rheumatoid 
arthritis, osteoporosis and cardiovascular diseases, whereas gum disease may also contribute 
to the risk of pregnancy complications such as preterm low-birth weight.3 
Tooth loss caused by periodontal health (which affects up to 20% of the adult population in 
the world) could result in significant morbidity and premature death. The economic impact of 
oral disease is one of the important considerations with up to 10% of public health 
expenditure in developed countries allocated to dental care.2 In most developing countries, 
spending in oral health care is much lower due to poor access to dental health care which is 
bounded and in general restricted to pain relief or contingency dental care.2,4 
The establishment of the relationships between oral disease and the activation of the 
microbial species that are part of the germs of the oral cavity is well defind.5 More than 750 
species of bacteria live in the oral cavity (50% of which have not yet to be identified) and a 
number of those involved in oral disease.5 The development of tooth decay involves 
acidogenic bacteria and aciduric Gram-positive bacteria, primarily the Streptococcus mutans 
and S. sobrinus, Lacobacilli and Actinomycetes, which metabolize sucrose to organic acids 
(lactic acid in the first place) that dissolve the calcium phosphate in teeth, causing 
decalcification and eventual decay. Dental caries is thus supragingival condition.6 On the 
other hand, periodontal diseases are conditions under the gum that are linked to the Gram-
negative bacteria such as Actinobacillus sp, Prevoella sp, Porphyromonas gingival and 
Fusobacterium sp.5,7 In periodontal disease, the areas at or below the gingival crevice 
become an infected incision which causes cellular inflammatory responses of the gums and 
 
 
 
 
CHAPTER 1 | 1.3 Tooth Decay 
3 
surrounding connective tissue. These inflammatory responses can manifest as gingivitis (very 
common and palpable as bleeding from the gums or gingival tissue) or periodontitis (the 
inflammatory response results in loss of collagen attachment of the tooth to the bone and loss 
of bone).6  
1.3 Tooth Decay 
Tooth decay occurs by the acid on the surface of the enamel. Acid is produced when sugars 
(mainly sucrose) in foods or beverages interact with bacteria in the dental biofilm (plaque) on 
the surface of the teeth. Acid production leads to loss of calcium and phosphate from the 
enamel. This process is called demineralization.8 Saliva works to weaken and neutralize the 
acid that causes demineralization. The enamel demineralizes and remineralizes many times 
during the course of a day. When the enamel ionic balance is constantly disrupted and 
demineralization exceeds remineralization tooth decay progresses. When this happens a lot 
and demineralization exceeds remineralization over several months, while purification occurs 
persistently and exceeds remineralization over time and over many months, there is a 
collapse of the enamel surface which leads to a cavity. Cavities, even in children who do not 
have their permanent teeth, can cause serious complications such as pain, tooth abscess, tooth 
loss, broken teeth, chewing problems and serious infections.9 
1.4 Caries Process 
The basic concept of the process of caries of the teeth is simple and was first described more 
than 100 years ago. The teeth are wrapped by bacteria which specify the dental plaque.8,10 
Some of the bacteria in dental plaque have been identified, including such as mutans 
streptococci (e.g., Streptococcus mutans and S. sobrinus) and lactobacilli, which are 
acidogenic, i.e., they produce acids when the metabolism of carbohydrates enter a 
fermentation phase.8 These acids, such as lactic, acetic, propionic and formic acid can 
dissolve the mineral calcium phosphate from the tooth enamel or dentin.10 If this process is 
not halted or reversed, it progresses to carious lesions, eventually leading to a cavity. Many 
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carbohydrates such as glucose, sucrose, fructose or cooked starch can be metabolized by 
these bacteria with the evolution of organic acids (e.g., propionic, lactic, acetic) as 
byproducts.11 The acids diffuse through the plaque and porous enamel (or dentin, if exposed), 
dissociating to produce hydrogen ions.12 Hydrogen ions melt the metal easily, and release 
calcium and phosphate into solution, which can be spread from tooth. This is 
demineralizationor, or loss of mineral as illustrated in Figure 1.1.9 
 
 
Figure 1.1: Schematic of acid production by plaque bacteria, followed by tooth demineralization  
1.5 Streptococcus mutans 
Streptococcus mutans is a facultatively anaerobic, Gram-positive bacterium commonly found 
in the human oral cavity and is a significant contributor to tooth decay. The microbe was first 
described by J Kilian Clarke in 1924.13 Streptococcus belongs to the firmicutes family and a 
group of lactic acid bacteria. S. mutans, a member of the human oral flora, is widely 
recognized as the main factor that causes tooth decay. Conditions in the oral cavity are 
influenced by a diversity of oral resident microbiota and commensal flora, and their usual 
balance with the host can change from one extreme to another, leading to the emergence of 
potentially pathogenic bacteria. S. mutans must tolerate the harsh environmental fluctuations 
quickly upon exposure to various antimicrobial agents to survive. Streptococci represent 20% 
of the oral bacteria and, along with sucrose, essentially determine the development of 
biofilms.14-16 Even though Streptococcus mutans could be antagonized by the leading oral 
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colonists, once they become dominant in mouth biofilms, tooth decay can develop and 
thrive.17 Figure 1.2 shows S. mutans stained in a thioglycollate broth culture. 
 
Gram stain. Thioglycollate broth culture. Morphology is rod-like with chains when cultured on broth. Can cause subacute 
bacterial endocarditis and dental caries. Centers for Disease Control and Prevention's Public Health Image Library (PHIL), 
with identification number #1043 
Figure 1.2: Streptococcus mutans stained in a thioglycollate broth culture 
While S. mutans grow in biofilm cells maintain a balance of metabolism involving the 
production and detoxification reactions. Biofilm is the sum of microorganisms and the cells 
that are committed to each other or the surface. Bacteria in the biofilm community can 
actually generate various toxic compounds that interfere with the growth of other competing 
bacteria. However, there have been very few studies on how to S. mutans can tolerate such an 
exposure to various toxic substances during their growth in the oral biofilm. Therefore, it is 
understandable that over time S. mutans developed strategies to successfully colonize and 
maintain a dominant position in the oral cavity. 
1.6 Traditional Herbal Medicine and Oral Care 
Medicinal plants have been used as traditional treatments for different diseases that affect 
humans for thousands of years in many parts of the world. In rural areas in developing 
countries, they continue to be used primarily as a source of medicine.18 Around 80% of 
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African populations use traditional medicines to take care of their health.19 Natural products 
derived from medicinal plants have proved to be a source of abundant bioactive compounds, 
many of which were the basis for the development of new lead chemicals to pharmaceuticals. 
The many diseases caused by microorganisms, and the increasing incidence of resistance 
among common pathogens to currently used therapeutic agents, like antiviral agents and 
antibiotics, has led to a renewed interest in the discovery of new anti-infective compounds. 
Of the nearly 500,000 species of plants that occur in all parts of world, only 1% has been 
investigated phytochemically, and there great potential for discovery of newer biologically 
active compounds.1 
Globally, the need for protection options and alternative products for oral diseases and 
treatments that are safe, effective and economical comes from the increase in the infection 
rate (especially in developing countries), the increase in the resistance of pathogenic bacteria 
to currently used antibiotics and chemotherapeutics, in addition to opportunistic infections in 
immunocompromized individuals.7,20 Although many agents are commercially available, 
these chemicals change the oral bacteria and have undesirable side effects such as vomiting, 
diarrhoea and staining of teeth.19 
1.7 Traditional Plants Used to Treat Periodontal Diseases 
There have been numerous reports of the use of traditional herbal medicine and pure natural 
compounds for the treatment of oral disease. Early studies have clearly confirmed that a 
number of substances had the potential to be used in the dental industry, due to their activity 
against cariogenic bacteria and the bacteria associated with periodontal disease. Several 
studies have investigated the activity of traditional plants against oral pathogens and the 
examination were mainly to validate the traditional use of the medicinal plants.  
1.7.1 Drosera peltata (Droseraceae) 
The use of Drosera peltata as a traditional treatment for tooth decay have been amply 
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validated. The chloroform extract of the aerial plant parts shows broad spectrum activity 
against many bacteria of the oral cavity, with greatest activity against S. mutans and S. 
sobrium (MIC=31.25 and 15.625 μg/ ml, respectively).21 Plumbagin has been identified as 
the active ingredient of this extract which gave MIC values of 1 μg/ml against S. mutans and 
S. sobrinus and 2 μg/ml against S. rattus and S. cricetus. 
1.7.2 Rhizoma coptidis (Ranunculacea) 
The water extract of R. coptidis, a traditional Chinese medicinal plant, showed bactericidal 
activity against oral bacteria, especially against periodotopathogenic bacteria (MIC=31-
250 μg /ml).22 
1.7.3 Hamamelis virginiana (Hamamelidaceae) 
Louk et al. assessed the ability of 10% decoctions and methanol extracts of a number of 
medicinal plants to inhibit bacterial isolates obtained from crevicular fluid of the periodontal 
pockets of periodontal patients. Generally, decoctions showed less activity than methanol 
extract. The extract from the leaves of Hamamelis virginiana had the greatest activity against 
all bacteria tested, with MIC values <512 μg/ml, particularly against Porphyromonas spp., 
Preveotella spp. and Actinomyces odontolitycus.23 
1.7.4 Allium sativum (Liliaceae) 
Allium sativum (garlic) has been used as a medicine since ancient time because of its 
antibacterial properties.24 Whereas garlic has been shown to have such activity against a 
broad range of bacteria, the particular activity against Gram-negative oral pathogens, 
including P. gingivalis was only recently demonstrated. The garlic extract contains the major 
antimicrobial component, allicin, which is less active against Gram-positive bacteria (MIC 
range 35.7-142.7 mg/ml garlic; 13.7-55 μg/ml allicin), but more active toward a range of 
Gram-negative species (MIC range 1.1- 35.7 mg/ml garlic; 0.4-13.7 μg/ml allicin). The 
extract almost completely inhibited trypsin-like protease activity (implicated in the 
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pathogenesis of periodontitis) of P. gingivalis.24  
1.7.5 Harungana madagascariensis (Hypericaceae) 
H. madagascariensis is a native African plant which contain numerous antimicrobial 
components.25 Using successive soxhlet solvent extraction, an ethyl acetate extract of leaves 
was prepared and tested against many oral pathogens. While the extract was able to kill all 
the oral bacteria tested (including Streptococcus species, Lactobacillus, Propionibacterium, 
Fusobacterium Actinomyces and Prevotella), poly (D-L-lactide-co-glycolide) nanoparticles 
containing extract showed promosing activity, with minimal bactericidal concentration 
(MBC) ≤5×102 mg/l, except for Lactobacillus casei with 7.5×102 mg/l. The authors 
suggested that this might be due to the bioadhesive polymer properties, which led to the 
extraction being in contact with the bacteria for prolonged periods.25 
1.7.6 Pistacia lentiscus (Anacardiaceae) 
Resin exuded by P. lentiscus (Anacardiaceae) tree, known as the Mastic Gum, has been 
shown to have antimicrobial activity and is used in the preparation of food and as treatment 
for oral malodor, but the low solubility suggested that it might be useful for local application 
rather than a mouth rinse.26 The P. vera extract has also been shown to possess antibacterial 
activity against oral Streptococci (MIC>1 mg/ ml), including the inhibition of adherence and 
glycolysis.27 
1.7.7 Piper cubeba (Piperaceae) 
An ethanol extracts of P. cubeba showed good antibacterial properties against a range of 
cariogenic pathogens (MIC=90-200 μg/ml). The ethanol extract was more active against S. 
salivarius (MIC value of 80 µg/ml). (-)-Cubebin displayed MIC values ranging from 0.20 
mM for Streptococcus mitis to 0.35 mM for Enterococcus faecalis.28 
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1.7.8 Helichrysum italicum (Compositae) 
H. italicum is widely found in the Mediterranean region and has been shown to have an 
assortment of biological properties. An ethanol extract of powdered flowering tops was 
demonstrated to have antimicrobial activity against S. mutans, S. sanguis and S. sobrinus, 
with MIC values of 31.25-62.5 μg/ml.29  
1.7.9 Salvadora persica (Salvadoraceae) 
S. persica is a plant growing in the deserts from the region of western India to Africa. Other 
names for this plant are the Arak tree, chewing stick, natural toothbrush and Miswak or 
Siwaak. S. persica showed affectivity to prevent dental caries if it is used for a long time.30 S. 
persica has been used for centuries as a traditional method for cleaning teeth. Roots of S. 
persica have been demonstrated to possess antimicrobial activity and produce a number of 
antimicrobial substances. The BITC (benzyle isothiocyanate) is the main antimicrobial 
component with high killing activity against Gram-negative periodontal pathogens.31 S. 
persica has antimicrobial effects against S. mutans and S. faecalis. Also, it has been showed 
that S. fecalis is the most sensitive microorganism affected by S. persica.32 
1.7.10 Euclea natalensis (Ebenaceae) 
E. natalensis is an African traditional medicinal plant. The root is used for cleaning teeth and 
the gums with a chew, in the belief that it benefits the health of the mouth and teeth.33 The 
root of E. natalensis contains napthoquinones which are bactericidal.33 Moreover, the root 
extract of the plant showed strong antibacterial activity against S. mutans. The authors 
suggested that the regular use to the E. natalensis might control the formation and activity of 
dental plaque and therefore reduce the incidence of gingivitis and possibly of dental caries.34 
Another study showed that the ethanol extract of E. natalesis has a positive inhibitory 
activity against five oral pathogens (Actiomyces naeslundii, Actimyces israelii, 
Porphyromonus gingivalis, Privotella intermedia and S. mutans).35  
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1.7.11 Psoralea corylifolia (Fabaceae) 
The antimicrobial activity of P. corylifolia leaves and its corresponding callus extract were 
tested against pathogenic bacteria causing periodontitis. The leaf callus methanol extract was 
found to be more effective against the pathogenic bacteria.36,37 Bakuchiol have been isolated 
from the seeds of P. corylifolia, and showed bactericidal effects against many oral bacteria, 
including Streptococcus sanguies, S. salivarius, S. mutans, S. sobrinus, Enterococcus 
faecalis, E. faecium, Lactobacillus acidophilus, L. casei, L. plantarum, Actinomyces viscosus 
and Prophyromonas gingivalis. The bakuckiol might be a useful compound for the 
development of antibacterial agents against oral pathogens and also has a great potential to be 
used in food additives and mouth rinses to prevent and treat dental caries.36,38  
1.7.12 Azadirachta indica (Meliaceae) 
A. indica (Neem) is commonly used as oral hygiene tools in different parts of the world. 
Neem has been considered to have various activities such as anti-ulcer and for cleaning the 
teeth in pyorrhea and other dental diseases. Leaves of the Neem have been used in the 
treatment of gingivitis and periodontitis. Neem has also showed enhanced efficacy in the 
treatment of oral infections and plaque growth inhibition in treating periodontal disorders. 
Neem has a good in vitro broad range antibacterial activity39,40. Several studies have 
demonstrated the antibacterial activity and the anti-plaque anticarious propertiesof A. indica. 
Almas K reported that Neem chewing stick extract are effective at 50% concentration on S. 
mutans and S. facealis 32,41. 
1.7.13 Other Plants 
Two recent studies examined the number of plants traditionally used in Brazil42 or South 
Africa,35 respectively, for activity against oral pathogens Prevotella intermedia, 
Porphyromonas gingivalis, Fusobacterium nucleatum, S. mutans and Lactobacillus casei. 
Four Brazilian plant extracts, Aristolochia cymbifera (Aristolochiaceae), Ziziphus joazeiro 
(Rhamnaceae), Caesalpinia pyramidalis (Fabaceae) and Cocos nucifera (Palmae), were 
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shown to be active against the bacteria tested, with the ethanol extracts of A. cymbifrica 
being the most effective. Plants in South Africa (Annona senegalensis, Englerophytum 
magalismontanum, Dicerocarym senecioides, Euclea divinorum, Euclea natalensis, Solanum 
panduriforme and Parinari curatellifolia) were also tested, and all proved effective. In the 
case of Breynia nivosus (Euphorbiaceae) and Ageratum conyzoldes (Asteraceae), cold and 
hot water and ethanolic extracts were tested for activity against S. mutans—the hot water and 
ethanol extracts showed weak activity (MIC>25 mg/ ml).43 Another study determined the 
ability of commercially available food that contain a high proportion of polyphenol to 
prevent the growth of S. mutans and other oral pathogens.44 All extracts showed activity, with 
an extract of red grape seeds exhibiting the greatest activity against S. mutans 
(MIC=500 μg/ml). The unfermented cocoa extract and green tea were most active against 
other oral pathogen. The various extracts were also able to prevent the adhesion S. mutans on 
glass. These data indicate that extracts of polyphenol-containing foods might have a 
protective role against dental caries.44  
An investigation of a group of 27 medicinal plant extracts to identify the number that inhibits 
the growth of oral Streptococci showed that the most active extracts included those from 
Abies canadensis (Pinaceae), Chelidonium majus (Papaveraceae), Albizia julibrissin 
(Fabaceae), Juniperus virginiana (Cupressaceae), Pinus virginiana (Pinaceae), Ginkgo 
biloba (Ginkgoaceae), Rosmarinus officinalis (Lamiaceae), Tanacetum vulgare (Asteraceae), 
Thuja plicata (Cupressaceae) and Sassafras albidum (Lauraceae).7  
1.8 Problem Statement 
Dental caries is a major problem worldwide—Streptococcus mutans is a primary cause. The 
use of conventional preventive methods have proven effective in managing dental caries, 
however, excessive use of these synthetic products can change oral flora and cause other 
dental problems. For these reasons, there is a dire need to develop more efficacious 
anticariogenic compounds from alternative sources, including unexplored medicinal plants. 
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Many studies have investigated the antibacterial activity of different medicinal plant extracts 
against S. mutans, but there are few reports on the antibacterial potential of Psoralea 
fruticans, especially its chemical constituents which may be used effectively against S. 
mutans. The rationale of this study was to determine the antibacterial potential of the total 
extracts and chemical constituents of P. fruticans against S. mutans. 
1.9 Aim of the Study 
The initial aim of the study was to determine the antibacterial activity of extracts of 31 South 
African medicinal plants, collected randomly from the Cape Flats region against S. mutans. 
This led to the isolation and identification of bioactive compounds from Psoralea fruticans 
and, finally, biological evaluation of the pure isolated compounds for cytotoxicity against the 
normal human diploid fibroblast cell line (KMST-6).45 
1.10 Research questions of this study 
1. What are the possible active extract(s) from the 31 plants collected from the Cape 
Flats region? 
2. Does all the isolated compounds have antibacterial activity against S. mutans?  
3. How we can isolate them? 
4. What type of secondary metabolites exist within the active extract?  
5. Can these compounds prevent S. mutans biofilm formation?  
6. Are these compounds toxic to a normal human cell line? 
1.11 Objectives of this study 
The main objective of the study are: 
1. Collection of sample from their natural habitats, documentation and 
identification. 
2. Prepareation of metahanolic extracts from collected sample. 
3. Antibacterial evaluation of the plant extracts. 
4. Isolation of pure compounds from Psoralea fruticans. 
5. Identification of the isolated compounds and biological evaluation of thise 
compounds. 
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CHAPTER 2 
SCREENING OF THE PLANT EXTRACTS AGAINST S.MUTANS 
AND BIOFILM FORMATION 
2.1 Introduction  
Throughout history, natural flora have served as a source of alternative medicines, new 
pharmaceuticals, health care products and medicinal plants and are important for drug 
development and pharmacological research, not only when plant constituents are used 
directly as therapeutic agents, but also as starting materials for the synthesis of drugs or as 
models for pharmacologically active constituents.46 The antibacterial activity of plant extracts 
has been recognized for many years.47 Plant extracts have been used for a wide variety of 
purposes for many thousands of years.48 
In many parts of the world there is a long tradition of herbal medicine use for the treatment of 
many infectious diseases.49 Because of the side effects of and resistance pathogenic 
microorganisms develop against antibiotics, a lot of attention has recently been focused on 
extracts and bioactive compounds isolated from plant species. Herbal medicinal plants may 
offer a new source of antibacterial agents for use.50 Many drugs currently used to treat 
bacterial infections and other diseases have originally been isolated from natural sources, 
including medicinal plants.51  
One of the major rationales leading to the development and design of new drugs from plants 
is to examine the uses claimed in traditional folklore medicine. Many reports on the 
pharmacological investigatations of crude extracts have been published to validate the 
traditional uses.52 The aims of this study were to evaluate the antibacterial activity of 31 
medicinal plant extracts on Streptococcus mutans (ATCC 25175), the bacteria that causes 
dental caries and to determine their minimum inhibitory concentration (MIC) as well as the 
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minimum microbicidal concentration (MMC) by the microdilution technique using 96-well 
plates.53  
2.2 Materials and Methods  
2.2.1 General Reagents 
The following general reagents were used in this study (Table 2.1). 
Table 2.1: General reagents and equipment used in this study 
Chemicals Supplier 
Streptococcus mutans ATCC ® 25175TM 
Quantum Biotech 
Brain heart infusion 
Nutrient broth media 
Tryptic soy agar 
Glycerol Merck 
p-Iodonitrotetrazolium chloride (INT) 
Sigma Aldrich 
Neomycin antibiotic 
Dimethyl sulfoxide (DMSO) 
Fluoroshield Tm with DAPI (4',6-Diamidino-2-phenylindole) 
Acetic acid 
Methanol 
Bisphenol-S (BPS) 
Instruments 
96-well culture plates 
Olympus 6-well culture plates 
Olympus microscopes 
Vortex mixer 
Lasec 
Microscope slides 
Plastic loops 
Cover slides 
Incubator 
Forma Scientific 
Autoclave 
Benchtop centrifuge Beckman-Coulter 
Polystar omega microplate reader BMG Labtech 
Florescence microscope Carl-Zeiss 
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2.2.2 Reagents and Solvents for Extraction 
Methanol was bought from Crest Chemicals, South Africa. Ethyl acetate, and sulphuric acid 
from Kimix, South Africa.Vanillin was purchased from Merck Schuchardt, Germany. 
2.2.3 Solvent Evaporation 
The Rotavapor model Buchi Rotavapor RE 111 was used for solvent evaporation at 45°C. 
2.2.4 Thin Layer Chromatography (TLC) Plates 
Pre-coated plates of silica gel 60 F254 (Merck, Germany) was used for TLC analysis. 
Visualization of TLC plates was done by observing the bands or “spots” under UV at λ254 
nm and λ366 nm using a UV lamp (CAMAG, Switzerland), and by spraying with the 
vanillin/sulphuric acid reagent.54,55 
2.2.5 Plant Collection 
The plants were randomly collected from the Cape Flats Nature Reserve and surrounding 
areas, including the University of the Western Cape (UWC) campus in Cape Town, South 
Africa, in November 2012. except for Aspalathus linearis which was collected from local 
market (Afriplex, Cape town, South Africa) A herbarium was set up for each plant collection, 
and identified by Mr Frans Weitz (Department of Biodiversity and Conservation Biology, 
UWC) and deposited at the UWC herbarium (Table 2.2). 
2.2.6 Plant Extraction 
A known weight of each plant material (450g) was blended using a Waring blender with 
methanol (2.5 L) to increase the surface area and ease the extraction within little time. The 
blended plant material was soaked in a glass jar, warmed at 60°C for one hour and left for 24 
hours at room temperature. The material was then filtered, and the residue extracted with 
fresh MeOH. The filtrate was concentrated in vacuo at reduced pressure using a Rotavapor. 
The dried crude extracts were transferred into labelled and washed vials and kept cooled until 
further use.  
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Table 2.2: List of plants collected for this study 
No. Plant Name Family TLC No. Herbarium Used Part 
1.  Brunsvigia orientalis Amaryllidaceae 13 Hu- 44 Leaves 
2.  Searisa lucida Anacardiaceae 3 Hu- 22 Leaves 
3.  Searsia laevigata Anacardiaceae 5 Hu- 46 Leaves 
4.  Metalisia muricata Asteraceae 7 Hu- 1b Leaves 
5.  Athanasia trifurcate Asteraceae 25 Hu- 33 Leaves 
6.  Helichrysum cymosum Asteraceae 26 Hu- 47 Leaves 
7.  Helichrysm zeyheri Asteraceae 27 Hu- 18 Leaves 
8.  Helichrysm indicum Asteraceae 28 Hu- 43 Leaves 
9.  Athanasia crithmifolia Asteraceae 29 Hu- 22/1 Leaves 
10.  Arctotheca populifolia Asteraceae 31 Hu- 22/16 Leaves 
11.  Tarchonanthus camphoratus Asteraceae 32 Hu- 22/9 Leaves 
12.  Athanasia parvitflora Asteraceae 23 Hu- 20 Leaves 
13.  Senecio halimifolus Compositae 10 Hu- 8 Leaves 
14.  Scirpus antarticus Cyperaceae 12 Hu- 59 Leaves 
15.  Psoralea fruticans Fabaceae 4-17 Hu-5 Leaves 
16.  Psoralea pinnata Fabaceae 18 Hu- 54 Seeds 
17.  Psoralea pinnata Fabaceae 19 Hu- 55 Leaves 
18.  Aspalathus linearis Fabaceae 21 -------- Leaves 
19.  Aspulathus hispida Faboideae 11 Hu- 54 Leaves 
20.  Castanea sativa Fagaceae 34 Hu- 17/3 Leaves 
21.  Salvia africana caerulea Lamiaceae 1 Hu- 47a Leaves 
22.  Salvia africana lutea  Lamiaceae 14 Hu- 50 Leaves 
23.  S. africana lutea  Lamiaceae 15 Hu- 51 Root 
24.  Acacia karroo Leguminosae 16 Hu- 52 Leaves 
25.  Montania caryophyllacea Montiniaceae 33 Hu- 34 Leaves 
26.  Myrica quercifolia Myricaceae 8 Hu- 24 Leaves 
27.  Myrtus communis Myrtaceae 9 Hu- 42 Leaves 
28.  Phylica ericoides Rhamnaceae 6 Hu- 4 Leaves 
29.  Rosa canina  Rosaceae 20 Hu- 57 Fruit 
30.  Halleria lucida Stilbaceae 24 Hu- 27 Leaves 
31.  Passerina rigida Thymelaeaceae 2 Hu-3 Leaves 
32.  Lichtensteinia lacera Apiaceae 36 Hu- 17/1 Leaves 
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Passerina rigida Salvia african caerulea 
  
  
Searisa lucida Phylica ericoides 
  
  
Senecio halimifolius Metalasia muricata 
  
  
Aspalathus hispida Psoralea pinnats seeds 
All plant pictures were abstracted from Ispot in March 2015. www.ispotnature.org  
Figure 2.1: Pictures of plants collected for this study 
 
 
 
 
CHAPTER 2 | 2.2.6 Plant Extraction 
18 
  
Rose canina (Chinese) Aspalathus linearis 
  
 
 
Acacia karroo Salvia africana lutea 
  
  
Psoralea fruticans Myrica quercifolia 
  
  
Myrtus communis Athanasia trifurcata 
All plant pictures were abstracted from Ispot in March 2015. www.ispotnature.org  
Figure 2.1: Pictures of plants collected for this study (continued) 
 
 
 
 
CHAPTER 2 | 2.2.6 Plant Extraction 
19 
 
 
Montinia caryophyllacea Tarchonanthus camphoratus 
  
  
Athanasia crithmifolia Arctotheca populifolia 
  
  
Helichrysm zeyheri Helichrysm indicum 
  
  
Athanasia parvitflora Helichrysum cymosum 
All plant pictures were abstracted from Ispot in March 2015. www.ispotnature.org  
Figure 2.1: Pictures of plants collected for this study (continued) 
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Brunsvigia orientalis Senecio halimifolius 
  
  
Searsia laevigate Psoralea pinnata 
  
  
Halleria lucida Castanea sativa 
  
  
Scripus antarticus Lichtensteinia lacera 
All plant pictures were abstracted from Ispot in March 2015. www.ispotnature.org  
Figure 2.1: Pictures of plants collected for this study (continued) 
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2.2.7 Thin Layer Chromatography (TLC) 
1 mg of crude extract (1-32) were dissolved in 100 µl of methanol to form a homogeneous 
solution in vials 1 to 35. The extract was then spotted onto TLC plates (10 X 20 cm), and 
developed in two different solvent systems (1% MeOH/DCM) and (8% MeOH/DCM). 
2.2.8 Detection of Spots  
The developed plates were viewed under an ultra violet (UV) lamp at wavelengths 254 and 
366 nm. The TLC plates were sprayed with vanillin/sulphuric acid and gently heated 
according to the method described for plant drug analysis.54 Figures 2.2 and 2.3 show the 
TLC plates of different plant extracts developed with 1% and 8% dicholoromethane, 
respectively. 
2.2.9 Preparation of Stock Solutions of the Extract 
Approximately 10 mg of each extract was dissolved in 1 ml dimethyl sulphoxide (DMSO). 
Then 800 µl fresh nutrient broth medium was added to 200 µl of extract stock to a final 
concentration of 2 mg/ml. 
2.2.10 Bacteria 
Streptococcus mutans (ATCC 25175) was stored at -20°C. The bacteria were activated in 
brain heart infusion medium at room temperature and incubated for 24 hours at 37°C. After 
the incubation period, the Gram stain was carried out to check that the bacteria were clear 
and there was no contamination. 
2.2.11 Qualitative Screening of Plant Extracts by Bioautography 
The plant extracts were used to test for compounds with activatity against the 
microorganisms using a simple and direct assay on TLC plates. Approximately 1 mg of each 
extract was dissolved in 100 µl methanol and spotted on TLC plates. The plates were 
developed in 3% MeOH/DCM and sprayed with Streptococcus mutans and incubated in a 
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humid atmosphere to allow for bacterial growth for 24 hours at 37°C. After incubation, the 
plates were sprayed with p-iodonitrotetrazolium violet salt (INT) and incubated for 2 hours at 
37°C.56,57 The other plate was sprayed with vanillin/H2SO4 and heated.  
 
 
 
TLC plates (1-35) developed with 1% dicholoromethane (DCM)/methanol (MeOH) and visualized under a UV lamp at 
wavelengths λ254 nm (plate A), under λ366 nm (plate B) and after spraying with vanillin/sulphuric acid (plate C). 
Figure 2.2: TLC plates of different plant extracts developed with 1% dicholoromethane 
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TLC plates (1-35) developed with 8% dicholoromethane (DCM)/methanol (MeOH) and visualized under a UV lamp at 
wavelengths λ254 nm (plate A), under λ366 nm (plate B) and after spraying with vanillin/sulphuric acid (plate C). 
Figure 2.3: TLC plates of different plant extracts developed with 8% dicholoromethane  
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2.2.12 Screening of Plant Extracts for Antibacterial Activity 
The bacteria were transferred to nutrient broth media after centrifugation. The density was 
adjusted at 0.5 OD at 450 nm (McFarland standard) using a Polystar Omega microplate 
reader. All extracts were tested against S. mutans at two concentrations (500 and 100 µg/ml), 
then the plates were measured using a microplate reader. The first reading was just before 
incubation, then after 30 minutes, thereafter hourly over a period of 2 hours, then after 4 
hours and the last reading was taken after 24 hours of incubation. After incubation for 24 
hours at 37°C, microbial growth was indicated by adding 40 µl of 0.2 mg/ml p-
iodonitrotetrazolium violet salt (INT) to microplate wells and incubated at 37°C for 1 hour. 
Each extract was analyzed in triplicate. 
2.2.13 Determination of MIC and MMC 
The microdilution technique using 96-well plates as described by Eloff53 was used to obtain 
the minimum inhibitory concentration (MIC) and minimum microbicidal concentration 
(MMC) values of the crude extract against S. mutans. The active extracts were serially 
diluted in 96-well plates. The final concentration of extract and positive control (neomycin) 
ranged from 2 mg /ml to 0.005 mg/ml. Bacteria 24 hours old were add to the 96-well plate 
and incubated for 24 hours at 37°C, the density of bacteria was adjusted at 0.5 OD. Five 
concentrations were used to obtain the MIC (500, 250, 125, 62.5, and 31.25 mg/ml). The 
bacteria were treated with neomycin (positive control) and DMSO (negative control). 
Microbial growth inhibition was initiated by adding 40 µl of 0.2 mg/ml INT to microplate 
wells and incubated at 37°C for 1 hour. MIC was defined as the lowest concentration that 
inhibited INT colour change.  The MMC was determined by adding 50 µl of the suspensions 
from the wells, which did not show any growth after incubation during the MIC assay, to 150 
µl of fresh broth. These suspensions were re-incubated at 37°C for another 24 hours. The 
MMC was determined by adding 40 µl of 0.2 mg/ml INT to microplate wells and incubated 
at 37°C for 1 hour. The MMC was determined as the lowest concentration of extract that 
inhibited 100% growth of bacteria.58,59 
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2.2.14 Biofilm Formation 
The bacteria were activated in brain heart infusion medium and incubated for 24 hours at 
37°C. After incubation, the culture was allowed to develop a biofilm on glass slides using 6-
well plates. Approximately 50 µl bacteria and 50 µl fresh medium was cultured on a slide 
cover and incubated for 24 hours at 37°C. After incubation, the slide was either left untreated 
(negative control), treated with neomycin as a positive control or the MIC of the 8 active 
plants (Salvia Africana caeralea, Psoralea fruticans, Acaica karroo, Salvia Africana lutea, 
Psoralea pinnata, Helicrsyum cymosum, Helichrysum zeyheri and Castania sativa). After 24 
hours incubation, the slides were removed from the plate and rinsed in sterile PBS. The 
fixation was done using 100% MeOH for 10 min, then 70:30 acetic acid:MeOH for 30 min 
followed with 100% for 2 min. Then the slide was rinsed again with PBS and dried. The 
slides were stained with FluoroshieldTm with DAPI and examined using a florescence 
microscope.60 
2.3 Results 
2.3.1 Qualitative Screening Using TLC Bioautography 
After the incubation period, the colour was clear the active extracts doing inhibition zones on 
the plate, as illustrated in Figures 2.4 and 2.5. Equal volumes of different plant extracts were 
spotted on silica gel plate. After development the plate was left to dry and either sprayed with 
bacteria or vanillin/H2SO4 for direct comparison. The purple colour indicates that the bacteria 
are still alive and the colourless to yellow zone denotes dead bacteria. The plates showed the 
extracts that have inhibitory activity of bacteria as well as the location of the active 
compounds.61  
2.3.2 Microdilution Screening 
From the 31 extracts tested, 8 plants were active against Streptococcus mutans at 500 µg/ml, 
and 3 plants were active at 100 µg/ml (Table 2.3). The active plants were S. africana 
caerulea, Psoralea fruticans, S. africana lutea, Acacia karroo, Helichrysum cymosum, 
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Psoralea pinnata, Helichrysum zeyheri and Castanea sativa 3 at 100 µg/ml. Psoralea 
fruticans, Psoralea pinnata, and Helichrysum cymosum were active at a concentration 100 
µg/ml (Table 2.3, Figures 2.6 to 2.8). 
 
 
 
TLC plate A: sprayed with vanillin acid and heated; TLC plate B: TLC of the extracted plants, sprayed with S. mutans. 
Figure 2.4: Qualitative screening of plant extracts using TLC bioautography—1 
2.3.3 MIC and MMC 
Preliminary screening for the plant extracts showed activities of eight extracts at 500 µg/ml 
and three of them showed potential activity at 100 µg/ml. The eight plant extracts were 
investigated for their MIC and MMC values. Table 2.4 shows the corresponding values of the 
extracts under study. The extracts of P. fruticans and P. pinnata were found to be the most 
effective against S. mutans, both exhibiting MICs of 31.25 µg/ml and MMCs of 62.5 µg/ml.  
S. africana lutea, S. Africa caerulea, Acacia karro inhibited bacterial growth at an MIC of 
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62.5 µg/ml with MMC of 125 µg/ml. Helichrysum zeyheri, Helichrysum cymosum and 
Castanea sativa inhibited the growth of bacteria at 125 µg/ml with an MMC of 250 µg/ml. 
The positive neomycine control inhibited the growth of S. mutans of 0.01 µg/ml with MMC 
of 0.31µg/ml (Table 2.4). 
 
 
TLC plate A: sprayed with vanillin acid and heated; TLC plate B: TLC of the extracted plants, sprayed with S. mutans. 
Figure 2.5: Qualitative screening of plant extracts using TLC bioautography—2 
2.3.4 Streptococcus mutans Biofilm Formation 
All the slides which were treated with extracts showed biofilm formation. The florescence 
microscope images show the treated slides decrease compared to the untreated slides or the 
control. The untreated cells formed a biofilm while the cells treated with extracts inhibited 
the formation of a S. mutans biofilm. Some extracts can reduce the biofilm development as 
Posoralea fruticans and Salvia africana caerulea, while the other extracts showed 
development in the biofilm (Figure 2.9). 
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Table 2.3: Activity of extracts prepared from plants collected for this study 
Plant Extract 500 µg/ml 100 µg/ml 
Acacia Karroo Active Not Active 
Arctotheca populifolia Not Active Not Active 
Aspalathus linearis Not Active Not Active 
Aspulathus hispida Not Active Not Active 
Athanasia crithmifolia Not Active Not Active 
Athanasia parvitflora Not Active Not Active 
Athanasia trifurcata Not Active Not Active 
Brunsvigia orientalis Not Active Not Active 
Castanea sativa Active Not Active 
Halleria lucida Not Active Not Active 
Helichrysm indicum Not Active Not Active 
Helichrysm zeyheri Active Not Active 
Helichrysum cymosum Active Active 
Lichtensteinia lacora Not Active Not Active 
Metalisia muricata Not Active Not Active 
Montinia caryophyllacea Not Active Not Active 
Myrica quercifolia Not Active Not Active 
Myrtus communis Not Active Not Active 
Passerina rigida Not Active Not Active 
Phylica ericoides Not Active Not Active 
Psoralea pinnata (seeds) Not Active Not Active 
Psoralea fruticans Active Active 
Psoralea pinnata (leaves) Active Active 
Rosa canina Not Active Not Active 
S. africana lutea (root bark) Not Active Not Active 
Salvia africana caerulea Active Not Active 
Salvia africana lutea  Active Not Active 
Scirpus antarticus Not Active Not Active 
Searisa lucida Not Active Not Active 
Searsia laevigata Not Active Not Active 
Senecio halimifolus Not Active Not Active 
Tarchonanthus camphoratus Not Active Not Active 
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Wells that a contain pink colour are not active while the colourless to yellow wells are active. 
Figure 2.6: Microdilution screening colourimetric profiles of plant extracts active against 
Streptococcus mutans 
Table 2.4: MIC and MMC values for eight plant active extracts 
Plant Extract MIC (µg/ml) MMC (µg/ml) 
Salvia africana caerulea 62.5 125 
Psoralea fruticans 31.25 62.5 
S. africana lutea eloac 62.5 125 
Acacia karroo 62.5 125 
Psoralea pinnata 31.25 62.5 
Helichrysum cymosum 125 250 
Helichrysum zeyheri 125 250 
Castanea sativa 125 250 
Positive Neomycin Control 0.01 0.31 
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Each plant extract sample was assayed in triplicate. A pink colour indicates live bacteria whereas a yellow colour signifies 
dead bacteria. Some extracts had a colour. 
Figure 2.7: MIC colourimetric profiles of plant extracts active against Streptococcus mutans 
2.4 Discussion 
Of the 30 plants collected from the Cape Flats 32 extracts were generated and tested for their 
inhibitory activities against S. mutans. Initially, the plants extracts were screened at 500 and 
100 µg/ml. The results showed that the extracts from eight plants (Salvia africana caerulea, 
Psoralea fruticans, S. africana lutea, Acacia karroo, Helichrysum cymosum, Psoralea 
pinnata, Helichrysum zeyheri and Castanea sativa) were active at 500 µg/ml, while extracts 
from only three plants (P. fruticans, P. pinnata and H. cymosum) demonstrated activity at 
100 µg/ml. 
MICs determined from the eight active plant extracts ranged from 250 to 31.25 µg/ml. P. 
fruticans and P. pinnata produced the most active extracts with MICs of 31.25 and MMCs of 
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62.5 µg/ml, respectively. The results showed that 42% of the plant extracts were active at 
500 µg/ml while 9% were active at 62.5 µg/ml. Furthermore, two plant extracts showed an 
MIC at 31.25 µg/ml. These plant extracts were selected for further phytochemical evaluation 
to isolate their bioactive compounds. 
  
  
  
  
 
 
  
 
 
Figure 2.8: Absorbance values obtained for plant extracts evaluated by the microdilution technique 
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Salvia africans corulea Positive Control Control 
   
Acacia karroo Salvia Africana lutea Psoralea fruticans 
   
Helichrysum zeyheri Helichrysum cymosum Psoralea pinnata 
 
Castania sativa 
Figure 2.9: Streptococcus mutans biofilm formation after treatment with active plant extracts 
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The methnolic extract of P. fruticans was the most active against S. mutans with an MIC of 
31.25 µg/ml and MMC 62.5 µg/ml. Thus, P. fruticans was indicated for detailed chemical 
characterization based on antibacterial activity because no such published data could be 
obtained in the literature and its TLC profiles suggested that it may be a rich source of 
compounds with inhibitory potential against S. mutans. 
A study reported that the ethyl acetate extract of Acacia karroo showed antilisterial activity, 
exhibiting an MIC of 3.1 µg/ml against L. monocytogenes.60 In another study, the methanol 
extract of Acacia karroo and Salvia Africana were able to prevent growth of Mycobacterium 
smegmatis, Mycobacterium tuberculosis, Staphylococcus aureus, Klebsiella pneumoniae, 
Pseudomonas aeruginosa, Candida albicans and Microsporum audouinii). The Acacia 
karroo extract showed activity at MIC values below 100 µg/ml and S. africana showed the 
best activity with an MIC of 39.06 µg/ml against E. coli, S. aureus and M. audainii.62  
The aqueous extract of the dried leaves of Salvia lutea showed antimicrobial activity against 
Staphylococcus aureus at concentrations of 10 mg/ml and 5 mg/ml whereas the aqueous 
extract of dried leaves of Salvia carulea showed weak antimicrobial activity against the 
bacterium. No activity was demonstrated against Pseudomonas aeruginosa, Candida 
albicans or Mycobacterium smegmatis.63 Hilchrysum cymosum showed bactericidal activity 
against B. cereus and it was also active against S. aureus and S. pyogenes.64 S. mutans 
biofilms were developed using glass slides. Six active plants showed biofilms caused by cells 
as they adhered to each other. Salvia africana caerulea and P. fruticans showed a reduction 
in cell numbers and no development of a biofilm. 
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CHAPTER 3 
CHEMICAL CONSTITUENTS OF PSORALIA FRUTICANS AND 
BIOLOGICAL EVALUATION OF THE ISOLATED COMPOUNDS 
3.1 Introduction  
In recent years, natural products have been shown to be more comprehensive and promising 
agents for the prevention of oral diseases, especially plaque-related diseases such as tooth decay. 
This, together with the increased antimicrobial resistance to available oral therapies attracted 
keen interest in the search for new drugs that are cost-effective, natural or of artificial origin.40 
Cytotoxic activity tests are part of developing potential pharmaceutical products into a clinically 
acceptable drugs and provides a screening process to ascertain that the compounds being tested 
are not more harmful to the normal biological processes than the effects for which they are being 
tested.65  
Various natural compounds have particular reactions against biological systems and cytotoxic 
evaluation of plants extracts is essential before they could be considered for new drug 
development.66 Many plant extracts and isolated compounds have been used in vitro for 
cytotoxicity using diferrent human and animal cell lines.67 From the all tested extracts and 
according to the results obtained in the previous chapter, the methanolic extract of P. fruticans 
was the most active extract against S. mutans with an MIC of 32 µg/ml.  
To date, no publication has reported on the chemical and/or biological aspects of P. fruticans. 
These two reasons provided an impetus and justification to start the chemical study of thr 
methanolic extract of the plant to isolate and identify its main chemical constituents and evaluate 
the effects of isolated pure compounds against S. mutans.  
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Therfore, in this chapter the biological activity of the methanol extract of P. fruticans and 
isolated compounds against S. mutans are reported. The cytotoxicity activity of the crude extract 
of P. fruticans and isolated compounds is also reported for the normal KMST-6 fibroblasts cell 
line as measured colorimetrically by an in vitro assay using the water-soluble tetrazolium salt 
(WST-1, 2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2Htetrazolium, mono-sodium 
salt).68,69 
3.2 Literature Review on Genus Psoralea 
3.2.1 Taxonomy, Morphology and Distribution of Psoralea fruticans 
The taxonomy, morphology and distribution of Psoralea fruticans are summarized in Table 3.1 
and Figure 3.1 
Table 3.1: Taxonomy of Psoralea fruticans 
Kingdom Plantae 
Phylum Tracheophyata 
Class Magnoliopside 
Order Fabales 
Family Fabaceae 
Genus Otholobium 
Synonoym(s)—Homotypic Otholobium Fruticans (L.) 
Trifolium Fruticans (L.) 
Synonoym(s)—Heterotypic Psoralea aculeate Thunb 
Psoralea cuneifolia Dum 
Psoralea bacteatal 
Description Straggling subshrub to 40 cm. Leaves 3-foliolate, leaflets 
obovate, glabrescent; stipules cilicate. Flowers purple to 
violet, calyx sparsely silky and glandular, lowest sepal much 
larger, very prominent, accrescent. Sep-Dec. Mountain 
fynbos, 160-400 m. SW (Cape Peninsula).70 
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The genus of Psoralea contains a wide range of shrubs and herbs subsidiary to the sub-
papilionaceae family Fabaceae. The species, numbering about 120, are found in all parts of the 
tropical and subtropical regions of world. These plants are mainly found in South Africa (about 
45 species), Australia (15 species) and North America (30 species). However Psoralea plants are 
also present in Asia, North Africa, South America and the Mediterranean region. They are annual 
or perennial, and they usually grow in arid or semi-arid zones.  
The morphology of Psoralea genus is not very homogeneous. The habit of the species varies 
considerably; some attain a height of 15 feet, while others are low shrubs or diffuse herbs, while 
at least one species forms a dense cushion-like growth. A distinctive feature of the genus is the 
presence of resin glands on practically every part of the plant. Most species have leaves 
composed of three unequal leaflets, but some of them have one-foliated leaves, like P. martinii 
or the Indian P. corylifolia. The flowers have general shaped of the Papilionoideae family, 
usually are blue, purple, or yellow and the vast majority of species are sweetly scented flowers. 
The fruit is a small pod (3 to 8 mm long), indehiscent, one-seeded, and without albumen.71,72 
A: Live plant 
 
B: Distribution map 
Figure 3.1: Morphology and distribution of Psoralea fruticans  
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3.2.2 Chemistry of Psoralea genus 
Few studies on the Psoralea genus are found in the literature, however P. corylifolia, among 
other species, have been studied extensively and different secondary metabolites including 
coumarins, furanocoumarins, flavonoids, meroterpenoids and coumestanes have been reported. 
3.2.2.1 Coumarins 
The chemical studies of seeds of P. corylifolia revealed the presence of psoralen (1), psoralidin, 
psopsoralen or angelicin (2)73-75 coumarin (3)76. isopsoralenoside (4) and psoralenoside (5)77 and 
8-methoxypsoralen (6),75 as shown in Figure 3.2. Angelicin was also isolated from the 
dichloromethane extract of Psoralea glandulosa.78 Psoralen was reported from the leafy branch, 
flowers, fruits and roots of P. acaulis and P. bituminosa.73,79,80 
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Figure 3.2: Coumarins and furanocoumarins from Psoralea species 
3.2.2.2 Flavonoids 
Bavachalcone (7), bavachinin (8), isobavachin (9) have been isolated from the seeds of Psoralea 
corylifolia Linn. and from Psoralea fructus,81,82 corylifols C (10),83 6-prenylynarigenin (11),73,84 
coryfolia A (12),85 corylifolin (13),86 astragalin (14)75 and bavachin (15)81,82 were isolated from 
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the seeds of Psoralea corylifolia (Figure 3.3). 
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Figure 3.3: Flavonoid constituents isolated from Psoralea species 
3.2.2.3 Isoflavonoids 
Neobavaisoflavone (16), isobavachalcone,87 corylinin (17),75,88 daidzein (18),83 8-prenyldaidzen 
(19), corylin (20), erythrinin A (21), isoneobavaisoflavone (22),89 genstein (23),76 bavadin (24),90 
bavarigenin (25)85 and daidzin (26)90 have been isolated from the seed of Psoralea corylifolia 
(Figure 3.4). 
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Figure 3.4: Isoflavonoid constituents isolated from Psoralea species 
3.2.2.4 Comestance 
The compouds psoralidin (27),88 a new compound called psoraleflavanone (28),91 4",5"-
dehydroisopsoralidin (29)92 and sophoracoumestans-A (30) were isolated from the Psoralea 
corylifolia88 as illustrated in Figure 3.5. 
 
 
 
 
CHAPTER 3 | 3.2.2.5 Chalcones 
40 
O
O
OH
OHO
 
O
O
O
HO
OH
 
O
O
O
O
OH
 
27 28 29 
O
O
O
HO O
 
30 
Figure 3.5: Comestance constituents isolated from Psoralea species 
3.2.2.5 Chalcones 
The compounds brosimacutin G (31), bakuchalcone (32),83 a new compound, namely, 4,2'-
dihydroxy-2''-(1'''-methylethyl)-2''-3''-dihydro-(4'',5'',3',4')-furano chalcone (33),93 corylifol B 
(34),83 obavachromene (35), 4-O-methylbavachalcone (36)86 and corylifolinin (37) have been 
isolated from the seeds of Psoralea corylifolia82 as illustrated in Figure 3.6. 
3.2.2.6 Meroterpenoids 
The compound, bakuchiol (38), has been isolated from the seeds of the Psoralea corylifolia 
Linn. and from Psoralia glandulosa.94-96 Bisbakuchiols A (39), B (40),97 five novel 
compounds—psoracorylifols A-E (41-45)—have been isolated from the seeds of Psoralea 
corylifolia.98 The compund ∆1,3-Hydroxybakuchiol (46) was isolated from the methanolic 
extract of Psoralea corylifolia.84 The compounds cyclobakuchiol A (47), cyclobakuchiol B (48), 
3-hydroxybakuchiol (49), 12-hydroxisobakuchiol (50) and the compound kuchiol (51) were 
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isolated from Psoralea glandulosum96 as shown in Figure 3.7. 
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Figure 3.6: Chalcone constituents isolated from Psoralea species 
3.2.2.7 Miscellaneous Compounds 
The compounds uracil (52),88 p-hydroxybenzaldehyde (53), 6-prenylnarigenin84 and a new 
compound, namely methyl-4-hydroxybenzoat (54)92 and caryophyllene oxide (55) have been 
isolated from the dried fruits of Psoralea fruticans. The chemical compounds of the essential oils 
obtained by hydrodistillation from the aerial parts of Psoralea mutisii (Miq.), germacrene D 
(6.8%) (56) and β-caryophyllene (5.4%) (57). The major volatiles released by β-glucosidase 
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treatment of the aqueous plant residue were α-pinene (17.8%) (58) and tricyclene (5.6%) (59).99 
The same compounds were isolated independently with a new essential oil compound called y-
cadinene (60) the first to be reported from this plant.100 The compound anthraquinone (61) was 
representative of 3 speices of Psoralea (P. acaulis, P. bitumiosal and P. jaubertina fenzl)79 as 
depicted in Figure 3.8. 
3.2.3 Pharmacology of Psoralea genus 
Psoralea corylifolia Linn. is a plant of the family Fabaceae and distributed widely in China, 
India and Southeast Asia. Its fruit, known as fructose Psoraleae (Buguzhi in Chinese), is used 
traditionally to treat spermatorrhoea, pollakiuria, asthma, and nephritis.101 The seeds of P. 
corlyfolia have been used as a tonic, to treat uterine bleeding, and as a coronary vasodilatory 
agent in traditional Chinese medicine. Seeds are effective against leucoderma, leprosy, psoriasis, 
asthma, as a stomachic, anthelmintic and diaphoretic.74,84 
3.2.3.1 Anticancer Activity 
Psoralea corylifolia L., a traditional Chinese medicinal plant used to treat several diseases. The 
plant extracts have potent antibacterial, antitumour, antioxidant, anti-inflammatory, antifungal 
and immunomodulatory activity. A plethora of chemical substances such as psoralen, 
isopsoralen, bakuchiol, psoralidin, bakuchalcone, bavachinin, flavones, volatile oils and lipids 
are present in different parts of the plant. Extracts of P. corylifolia also show remarkable 
antitumour potential in preclinical studies.102,103  
3.2.3.2 Antibacterial Activity 
The alcoholic extract produced death of microfilariae and showed antimycobacterial activity.38 
Bakuchiol, one of the major constituent of P. corylifolia, has shown activity against numerous 
Gram-positive and Gram-negative oral phatogens (MIC=1-4 µg/ml).   
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Figure 3.7: Meroterpenoid constituents isolated from Psoralea species 
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Figure 3.8: Miscellaneous constituents isolated from Psoralea species 
It was able to inhibit the growth of S. mutans under a range of concentrations, pH values and in 
the presence of organic acids in a temperature-dependent manner also inhibited the growth of 
cells adhered to glass surface.37,74 The compounds corylifol A, corylifol B, corylidol C, 
neobavaisoflavone, isobavachalcone, isoneobavaisoflavone, bavachalcone, bavachin, bavachinin, 
corylin, 8-prenyldaidzein, bakuchalcone, brosimacutin G and erythrinin A were assayed for the 
antibacterial activities against two hospital pathogenic Gram-positive bacteria—S. aureus and S. 
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epidermidim in vitro. The compounds corylifol B, neobavaisoflavone, bavachinin and erythrinin 
A showed significant antimicrobial activity against S. aureus and S. epidermidis at the level of 
MICs 0.009-0.073 mM.  
The compounds corylifol B, neobavaisoflavone, bavachalcone and bavachin showed comparable 
antibacterial activites as the positive controls (bakuchiol and magnolol). The compounds 
isobavachalcone, bavachinin and erythrinin A were even stronger than that two well-known 
natural antimicrobial agaents, bakuchiol and magnolol.83  
The compounds, psoralidin, angelicin and psoralen that isolated from the seeds of P. corylifolia 
showed significant antibacterial activity against Gram-negative and Gram-positive bacteria. 
Psoralidin and angelicin showed efficacy against Gram-positive and gram-negative organisms, 
including Bacillus subltilis, B. cerius, B. megatrium, Staphylococcusaureus, Sarcinalutea, 
Streptococcus, B. haemolyticus, Escherichiacoli, Shigelladysenteriae, S. shiga, S. boydii, S. 
flexneri, S. sonnei, S. sarcinaceae, Pseudomonasaeruginosa. Psoralidin showed stronger activity 
against Gram-negative Shigella sonnei and S. flexneri. The compounds psoralen and angelicin 
exhibited the highest activity against Gram-positive S. aureus.74 
Coryifolinin isolated from the benzene extract of P. corylifolia produced coronary vasodilation 
and inhibitory action on Hela cells and an estrogenic effect.38 The essential oil in a dilution of 1 
in 50,000 and 1 in 10,000 has been found to kill Paramecia and Streptococci within 15 and 10 
min, respectively.104 The fruit extract inhibits the growth of Staphylococcus citrates, 
Staphylococcus aureus, Staphylococcus albus, including strains resistant to penicillin and other 
antibiotics. The compound psoralen shows strong inhibition of bacteria, including Microsporium 
canis, Microsporium gypseum, Trichophyton rubrum, Trichophyton mentagrophytes, S. aureus, 
Candida albicans, Escherichia coli and P. aeruginosa.38  
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3.2.3.3 Anti-Inflammatory Activity 
The Psoralea fruticans plant has been included to the formulations of traditional medicines in 
Southeast Asia as a prophylactic against osteoporosis caused by senescence, and for the 
treatment of impotence, cold, painful lower back, enuresis, alopecia, psoriasis, and vitiligo.105 
The methanolic extracts from the seeds of P. corylifolia was found to inhibit production of nitric 
oxide (NO) in lipopolyaccharide-activated mouse peritoneal macrophages. The isolated 
compounds, bavachinin (IC50=26 µM), isobavachalcone (17 µM), neobavaisoflavone (ca. 29 
µM), corylifol A (ca. 21 µM) and psoralidin (ca. 23 µM) signiﬁcantly inhibited the accumulation 
of nitrite (NO2) as a marker of production of NO.84 However, the flavonone (bavachin and 
isobavachalcone) and isoflavones (neobavaisoflavone, corylifol A) and a coumarins (psoralidin) 
showed a moderate activity (IC50=17- ca. 29 µM), but the active compounds (isobavachalcone 
and psoralidin) and other prenylated flavanones (bavachin and 6-prenylnaringein) showed 
cytotoxic effects at a high concentrations (100 µM).84 
Bavachinin A isolated from fruits revealed marked anti-inflammatory, antipyretic, and mild 
analgesic properties at a dose of 25-100 mg/kg. It has demonstrated better antipyretic activity 
than paracetamol and it showed no effect on the central nervous system, and the maximum lethal 
dose was greater than 1000 mg/kg in mice.104 Bavachinin A also showed anti-inflammatory 
activity against carrageenan induced in rats.38 
3.2.3.4 Antioxidant Activity 
The powder and extracts of P. corylifolia Linn. were investigated in lard at 100°C by using the 
oxidant stability instrum (OSI). It was found to have a strong antioxidant effect. The isolated 
compounds were investigated individually and compared with butylated hydroxytoluene (BHT) 
and α-tocopherol by the OSI at 100°C. The results showed that corylifolin, corylin, psoralidin 
and bakuchiol had strong antioxidant activity, especially psoralidin had stronger antioxidant 
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property than BHT, but isopsoralen and psoralen had no antioxidant activities at 0.02% and 
0.04% levels.106 Bakuchiol showed broad antioxidant activities in rat liver microsomes and 
mitochondria.104 Bakuchiol showed weak inhibition at 10 µM, and the cytotoxic effects were 
observed at 30 and 100 µM using mouse peritoneal macrophages.84  
Bakuchiol oxidation was more potent in microsomes and inhibition of oxygen consumption 
induced lipid peroxidation dependent on time. Moreover, bakuchiol protects human red blood 
cells against oxidative haemolysis. These phenolic compounds in P.corylifolia are thus effective 
in protecting biological membranes against oxidative stress different.95 The flavonoids 
isobavachin and isobavachalcone and bakuchio were showed broad antioxidative activities in rat 
liver microsomes and mitochondria. They were found to inhibit NADPH-, ascorbate-, t-BuOOH- 
and CCl4-induced lipid peroxidation in microsomes. They also prevented NADH-dependent and 
ascorbate-induced mitochondrial lipid peroxidation.95 
3.2.3.5 Hepatoprotective Activity 
The water-soluble extracts containing bakuchiol has been found to possess hepatoprotective 
activity in tacrine-induced cytotoxicity in human liver-derived HepG2 cells. The IC50 value of 
bakuchiol was 1 µg/ml and of silymarin was 5 µg/ml.104 
3.2.3.6 Cytotoxicity 
Bakuchiol has been shown to possess a prominent cytotoxic effect on L929 cells in culture. It 
also showed cytotoxicity against cultured human cell lines, namely, A549, SKOV-3, SK-MEL-2, 
XF-498, and HCT-15.38 It was reported to inhibit the expression of INOS( Inducible nitric oxide 
synthase)  gene induced by interferon-γ and lipopolysaccharide in RAW macrophage-like cells at 
1-40 µM.107 The coumestan derivative, psoralidin, isolated from the seeds of P. corlifolia, 
exhibited potent cytotoxic activity against HT-29 (colon) and MCF-7 (breast) cancer cell lines 
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with the IC50 values of 0.3 and 0.4 µg/ml, respectively. The coumarin, angelicin, showed a weak 
cytotoxic against the HT-29 (colon) and MCF-7 (breast) cancer cell lines with the IC50 values 
17.7 and 11.9 µg/ml, respectively. Psoralen was considered to be inactive in the cytotoxic assay 
in this study.105 It also showed a cytotoxic effect on stomach cancer cell lines with IC50 value of 
53 µg/ml in SNU-1 and 203 µg/ml in SNU-16.104 
3.2.3.7 α-Glucosidase and α-Mannosidase Activity 
The seeds of P. corylifolia were extracted using five different polar solventss: chloroform, 
methanol, 50% ethanol in water, water and ethanol. The chloroform extract showed the lowest 
IC50 value against α-glucosidase (82.9 µg/ml) and α-mannosdase (132 µg/ml). The isolated 
compounds possessed α-glucosidase inhibitory activities. Also, the compounds posralidin and 
corylifol A which exhibited potent inhibition with IC50s of 13.7, 27.7 and 11.3 µM, respectively. 
Furthermore, compunds 4’-O-methylbavachalcone and posralidin showed α-mannosdase 
activity. Compounds psoralidin and neobavaisoflavone in the mechanistic analysis of inhibition 
mode against α-glucosidase showed noncompetitive inhibition, while that of corylifol was 
mixed. Interestingly, the most active glycosidase inhibitors were 4’-O-methylbavachalcone, 
posoralidin and corylifol A.86 
3.2.3.8 Antidepressant Activity 
A study of the antidepressant activity of total furanocoumarins present in P.corylifolia (TFPC) in 
the chronic mild stress model of depressed in mice revealed that TFPC possess potent and rapid 
antidepressant properties that are mediated via monoamine oxidase in the hypotohalamic-
pituitary-adrenal axis oxidative system. Thus, it makes P. corylifolia a potentially valuable drug 
to treat depression in the elderly.108 Other researchers also proved psoralen’s antidepressant 
effects, using forced swimming test model of depressed on male mice.109  
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3.3 Materials and Methods 
3.3.1 Materials 
The specific reagents and equipment used in this study are outlined in Table 3.2. 
3.3.2 Isolation and Characterization of Chemical Structures 
3.3.2.1 Column Chromatography 
Glass columns (different diameters) packed with silica gel 60 (0.063-0.0200 mm, Merck), were 
used for column chromatography. 
3.3.2.2 High Performance Liquid Chromatography (HPLC) 
Sample purification was carried out using Agilent Technologies 1200 series, equipped with UV 
detector, manual injector, quaternary pump (G1311A), vacuum degasser (G1322A), column 
compartment (G1316A) and reversed phase C18 column SUPELCO (25 X 1.0 cm). The flow 
rate was set at 1.5 ml/min and detection wavelength at λ254 nm. 
3.3.2.3 Nuclear Magnetic Resonance (NMR) Spectroscopy 
NMR spectra were recorded at 25°C, using CDCl3 as solvent, on a Bruker Avance 400 NMR 
spectrometer (1H 400 MHz, 13C 100 MHz). Chemical shifts of 1H (δH) and 13C (δC) in ppm 
were determined relative to solvent signal. 
3.3.2.4 Mass Spectroscopy (MS) 
High resolution mass spectroscopy (HRMS) analysis was conducted using a Waters Synapt G2 
Accurate Mass spectrometer using electrospray ionization (ESI) interface working in positive 
mode.  
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Table 3.2: Specific reagents and equipment used in this study 
Chemicals Supplier 
Dulbecco‘s modified Eagle’s medium (DMEM) 
Lonza Phosphate buffered saline (PBS) 
Penicillin-streptomycin 
Foetal bovine serum (FBS) Thermo Scientific 
Trypan blue stain (0.4%) Invitrogen 
Trypsin Gibco 
Dimethyl sulfoxide (DMSO), dichloromethane (DCM) 
Sigma-Aldrich or Merck 
Acetic acid, acetonitrile (ACN, HPLC grade), vanillin 
Methanol, ethyl acetate (EtOAc), Hexane (Hex) 
Fluoroshield with 4',6-diamidino-2-phenylindole (DAPI) 
Bisphenol-S (BPS), sulphuric acid 
Commercial kits  
Cell proliferation reagent (WST-1) Roche 
Instruments 
Cell culture flasks (25 cm2) SPL Life Sciences 
96-Multiwell culture plates Sigma-Aldrich 
Centrifuge 5417R Eppendorf AG 
CO2 incubator Shellab 
Countess II Fl Automated Cell Counter 
Invitrogen/Thermo Scientific 
Countess™ cell counting chamber slides 
Tali ® Image-Based Cytometer 
Tali ®cellular analysis slides 
POLARstar Omega Microplate Reader BMG Labtech 
Sorvall TC-6 Centrifuge Sorvall 
Cover slides 
Zeiss 
Florescence microscope 
  
 
 
 
 
CHAPTER 3 | 3.3.2.5 Ultra Violet (UV) Spectroscopy 
51 
3.3.2.5 Ultra Violet (UV) Spectroscopy 
A UV Nicolet Evolution (EV-100, Version 4.60) Spectrophotometer (Therma Electron 
Corporation, Madison, USA) was used for measurement of absorbance maxima between the 
wavelengths 200-450 nm. 
3.3.2.6 Infrared (IR) Spectroscopy 
Attenuated total internal reflectance Fourier transform infrared spectroscopy (FTIR) 
measurements were carried out using Spectrum 100 (PerkinElmer). Spectra recordings were 
accomplished using the Interface-Spectrum. Methanol was used to dissolve the samples. 
3.3.3 Sample Collection and Identification 
Psoralea fruticans was collected in August 2011 from the Cape Flats Nature Reserve, University 
of the Western Cape (UWC). The samples were collected by Dr Ahmed Mohammed (Chemistry 
Department, UWC) and identified by Mr Frans Weitz (Biodiversity & Conservation Department, 
UWC).  
3.3.3.1 Preparation of Total Extract 
The sample was collected and left to dry at room temperature (~25°C). Approximately 90.6 g of 
the dried plant was blended in MeOH. The extract was then warmed at the 60°C (in a water bath) 
for one hour and left overnight. The extract was filtered using Whatman filter paper and the plant 
residue was washed twice with fresh solvent. The combined total extracts were evaporated and 
the residue (19.03 g, 21.0 %) was kept at ~ 0°C, until used. 
3.3.3.2 Fractionation of Total Extract 
The extract (19.03 g) was applied to a silica gel column (7 X 27 cm, 500 g silica gel) (Figure 3.9) 
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and eluted using a mixture of Hex:EtOAc of increasing polarity, according to Table 3.3.  
Table 3.3: Solvent system used for fractionation of the total extract of Psoralea fruticans 
Solvent (%v/v) Volume (Litre) Fraction Combined Notes  
Hex 1 
1 
I 
 
2  
Hex:EtOAc 90:10 2 
3 
II 
Purified 
4 
5 
III 
6 
Hex: EtOAc 80:20 2 
7 
IV Purified 
8 
9 
10 
Hex: EtOAc 70:30 2 
11 
V Purified 
12 
13 
14 
Hex: EtOAc 60:40 2 
15 
VI  
16 
17 
18 
Hex: EtOAc 50:50 1 
19 
20 
VII 
 
 
Hex: EtOAc 40:60 1 
21 
VIII 
 
22  
Hex: EtOAc 30:70 1 
23 
IX 
 
24  
Hex: EtOAc 20:80 1 25 X  
EtOAc 100% 1 
26 
XI 
 
27  
EtOAc: MeOH 98:2 1 
28 
XII 
 
29  
EtOAc: MeOH 95:5 2 
30 
XIII 
 
31  
32  
33  
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Figure 3.9: Column chromatography setup 
46 different fractions (volume=500 ml) were collected. The fractions were concentrated and 
chromatographed on silica gel TLC plates (Figure 3.10) using different solvent systems 
[Hex:EtOAc 4:6, DCM:MeOH (90:10; 95:5) and EtOAc:acetic acid:formic acid:H2O (50:2:2:4)]. 
The fractions were pooled together according to their TLC profiles and were designated roman 
numerals (Table 3.3). 
3.3.4 Purification of Chemical Constituents 
3.3.4.1 Purification of Compounds 1-3 
Fraction III (3.5 g) was subjected to column chromatography (3 x 33cm) on silica gel and eluted 
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with gradient mixture of increasing polarity from Hex and EtOAc 99:1 to 93:7 to yield 65 sub-
fractions which were pooled together according to the TLC profile to six main fractions. 
 
A: TLC plate of main fractions (1-14) was developed using Hex:EtOAc (4:6) and visualized at λ254 nm (A), at 365 nm (A1) and after 
spraying with vanillin/H2SO4 (A2) 
B: TLC plate of main fractions (7-19) was developed using Hex:EtOAc (10:90) and visualized at λ254 nm (B), at 365 nm (B1) and 
after spraying with vanillin/H2SO4 (B2) 
C: TLC plate of main fractions (19-33) was developed using EtOAc:Acetic acid: formic acid:H2O 50:2:2:4 and visualized at λ254 nm 
(C), at 365 nm (C1) and after spraying with vanillin/H2SO4(C2) 
Figure 3.10: TLC chromatograms of fractions collected from the main column on silica gel 60 F254 
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The sub-fractions III2a (120 mg) was divided into two equal parts; the first (60 mg) underwent 
HPLC fractionation. 30 µl of sub-fraction III2 was injected into the HPLC column and eluted 
using a gradient system of MeOH and deionized water (DIW) (from 80:20 to 100 (MeOH) for 20 
minutes, then continuing with 100% MeOH for 40 min to wash) the two peaks at 27.9 and 29.0 
min were collected and examined by NMR. Peak 2 was pure compound (1) while peak 1 was a 
mixture of two compounds (2 and 3) (Figure 3.11). A trial to purify two compounds failed 
because of the small amount left after injection.  
 
Chromatograhic conditions 
Column: SUPELCO, RP18 (25 X 1) cm 
Solvent: MeOH:DIW: from 80:20 to 100 (MeOH) for 20 min, then continuing with 100% MeOH for 40 min. 
Flow rate: 1.5 ml/min 
Detection: UV at λ254 nm 
Figure 3.11: HPLC chromatogram of sub-fraction III2 
Fraction III2b (60 mg) second part (60 mg) was applied to prep-TLC of silica gel (20 X 20 cm) 
and eluted with MeOH:DCM (99:1). Three bands were collected; the first one was identical with 
compound 1, while bands 2 and 3 yielded pure compounds 2 and 3 (Figure 3.12).  
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Plate A:Visualized at λ254 nm; Plate B: Visualized at λ365 nm; Plate C: Sprayed with vanillin/H2SO4 and heated 
Figure 3.12: TLC plate for compounds 2 and 3 developed at 1% MeOH in DCM  
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3.3.4.2 Purification of Compounds 4 and 5 
Fraction IV (1.1 g) was subjected to column chromatography (3 x 34 cm) on silica gel and eluted 
with mixture of increasing polarity from Hex and EtOAc 95:5 to 88:12 to yield 46 sub-fractions 
which were pooled together according to the TLC profile to eight main fractions. Fraction IV2 
upon standing at room temperature formed crystals, which were carefully washed with hexane to 
yield pure compound 4 (5 mg). The sub fraction IV4 was injected into an HPLC chromatography 
column and eluted using MeOH:DIW (from 70:30, to 80:20 for 5 min, then continued to 100% 
for 35 min, washing through with 100% MeOH for 45 min); the peak at 29.0 min was collected 
to yield compound 5 (Figure 3.13). 
 
Chromatograhic conditions 
Column: SUPELCO, RP18 (25 X 1cm) 
Solvent: MeOH:DIW 70:80 for 5 min, to 100 % MeOH for 35 min, then washing through 100% MeOH for 45 min.  
Flow rate: 1.5 ml/min 
Detection: UV at λ254 nm 
Figure 3.13: HPLC chromatogram of fraction IV that yielded compound 5 
3.3.4.3 Purification of Compounds 6 and 7 
Fraction V (0.96 g) was subjected to column chromatography (3 x 35 cm) on silica gel and eluted 
with mixture of increasing polarity from Hex and EtOAc 90:10 to 70:30 to yield 46 sub-fractions 
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which were pooled according to their TLC profile to 12 main fractions. Sub-fraction V4 was 
injected into an HPLC chromatography column and eluted using MeOH:DIW (from 70% to 80% 
for 5 min, continued with 100% for 35 min, washing through 100% MeOH for 45 min). Two 
peaks at 13.5 and 33.0 min were collected to yield compounds 6 and 7 (Figure 3.14). 
 
Chromatograhic conditions 
Column: SUPELCO, RP18 (25 X 1cm) 
Solvent: MeOH:DIW 70:80 for 5 min, to 100 % MeOH for 35 min, then washing through 100% MeOH for 45 min.  
Flow rate: 1.5 ml/min 
Detection: UV at λ254 nm 
Figure 3.14: HPLC chromatogram of fraction V that yielded compounds 6 and 7 
3.3.5 Spectroscopic Details of Compounds 
Spectroscopic data for the isolated compounds are summarized in Figures 3.15 to 3.19, and the 
isolation procedure followed is provided in the flow diagram in Figure 3.20. 
3.3.5.1 Compound 1 
Yellowish oil; UV; λmax 230, 314 nm. IR: 3054, 2305, 1422, 1265, 1050, 895, 739, 705 cm-1; 1H 
and 13C NMR (CDCl3): HRMS-ES negative mode m/z 313.1804[M-H]+ (calculated for C20 
H26 O3, 314.4186). 
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3.3.5.2 Compound 2 
White, amorphous powder; UV: λmax 256, 298 nm. IR: 3054, 2305, 1422, 1265, 1050, 895, 739, 
705 cm-1; 1H and 13C NMR (CDCl3): HRMS m/z 205.494 [M-H]+ (calculated for C11 H10 O4, 
206.0579). 
3.3.5.3 Compound 3 
White, amorphous powder; [α]D25-1.5 (c 0.1, DCM); UV: λmax 260, 330 nm. IR: 3054, 2305, 
1422, 1265, 1050, 895, 739, 705 cm-1; 1H and 13C NMR (CDCl3): HRMS m/z 311.1674 [M-H] 
+ (calculated for C20 H24 O3, 312.1725). 
3.3.5.4 Compound 4 
White, amorphous powder; [α]D25-1.5 (c 0.1, DCM); IR: 3054, 2305, 1422, 1265, 1050, 895, 739, 
705 cm-1; 1H and 13C NMR (CDCl3): HRMS m/z 488.351 [M]+ (calculated for C30 H48 O5, 
488.3502). 
3.3.5.5 Compound 5 
Yellowish crystals; Mp 103-106. UV; λmax 324 nm. IR: 3054, 2305, 1422, 1265, 1050, 895, 739, 
705 cm-1; 1H and 13C NMR (CDCl3): HRMS m/z 313.1804 [M-H]+ (calculated for C20 H26 
O3, 314.1882). 
3.3.5.6 Compound 6 
White crystals; Mp 90-92. UV; λmax 230, 300 nm. IR: 3054, 2305, 1422, 1265, 1050, 895, 739, 
705 cm-1; 1H and 13C NMR (CDCl3): HRMS m/z 329.1748 [M-H]+ (calculated for C20 H26 
O4, 330.21831). 
3.3.5.7 Compound 7 
White, amorphous powder; [α]D25-1.5 (c 0.1, DCM); IR: 3054, 2305, 1422, 1265, 1050, 895, 739, 
705 cm-1; 1H and 13C NMR (CDCl3): HRMS m/z 488.351 [M]+ (calculated for C30 H48 O5, 
488.3502).   
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Figure 3.15: Spectroscopic data (UV (A), IR (B), 1H (C) and 13C (D) NMR) of compound 1  
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Figure 3.16: Spectroscopic data (UV (A), IR (B), 1H (C) and 13C (D) NMR) of compound 2  
 
 
 
 
CHAPTER 3 | 3.3.5.7 Compound 7 
62 
  
 
 
Figure 3.17: Spectroscopic data (UV (A), IR (B), 1H (C) and 13C (D) NMR) of compound 3  
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Figure 3.18: Spectroscopic data (UV (A), IR (B), 1H (C) and 13C (D) NMR) of compound 5  
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Figure 3.19: Spectroscopic data (UV (A), IR (B), 1H (C) and 13C (D) NMR) of compound 6  
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Figure 3.20: Schematic of isolation steps followed 
3.4 Results 
Screening of 32 plant extracts against S. mutans showed potent activity of the P. fruticans 
methanolic extract. The extract was subjected to chromatographic purification to yield seven 
pure compounds. Five of the isolated compounds are new metabolites isolated for the first time 
from a natural source, and belong to the geranyl derivative of coumaric acids (Figure 3-21). 
3.4.1 Psorticane A (1)  
The molecular formula of compound 1 (Figure 3-21) was determined by HRMS as C20H26O3. 
The NMR spectra (Figure 3.15) exhibited signals for four methyls, three of them are olefinic at 
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δH 1.66 (s, Me-8`), 1.58 (s, Me-9`), 1.74 (s, Me-10`), and methyl ester at 3.77, two olefinic 
proton at 5.30 (1H, td, J=7.2, 1.2 Hz, H-2`), and 5.06 (1H, br t, J=7.0 Hz, H-6``); three 
methylene groups two of them directly coupled to the above double bonds (as indicated from 
COSY and HMBC correlations) at 3.34 (CH2, d, J=7.2 Hz, H-1`), 2.08 (2 CH2, m, H-4`, -5`), the 
above data with carbon-13 signals [δC at 29.3 (C-1`), 121.1 (C-2`), 138.8 (C-3`), 39.6 (C-4`), 
26.4 (C-5`), 123.8 (C-6`), 131.9 (C-7`), 25.6 (C-8`), 17.7 (C-9`), and 16.2 (C-10`)] indicated the 
presence of geranyl group.110 
 
Figure 3.21: Chemical structures of compounds 1-7 isolated from P. fruiticans 
Additionally, the compound showed a typical signals of o-coumaric acid methyl ester [δH 6.8 
(1H, d, 8.8 Hz, H-3); 7.26 (2H, m, H-4, -6); 6.26 (1H, d, 16.0 Hz, H-8); 7.60 (1H, d, 16 Hz, H-
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7)/δC 127.6 (C-1), 156.8 (C-2), 116.1 (C-3), 127.7 (C-4), 126.9 (C-5), 130.1 (C-6), 145.2 (C-7), 
114.6 (C-8), 168.2 (C-9)]. The coupling pattern of the benzene ring required 1,2,5-trisubstituted 
system which indicates the location of the geranyl group at C-5, this fact was supported by the 
HMBC spectra which showed cross peaks (among others) between H-1`/C-4, C-6; H-6/C-1, C-5 
and H-7/C-6, C-2 Other 2D spectra HMBC, HSQC, and COSY confirmed the structure of 1 as 5-
geranyl o-coumaric acid methyl ester and given the trivial name psorticane A (Table 3.4). 
3.4.2 Compound 3 (Psorticane B) 
The molecular formula of compound 3 (Figure 3-16) was determined by HRMS as C20H24O3, two 
units less than compound 1. The 1H NMR spectrum showed signals of p-coumaric acid methyl 
ester similar to compound 1, the HMBC correlations were in agreement with the 1,3,4-
trisubstituted benzene ring as shown in Figure 3.22. The presence of cis coupled olefinic protons 
at 5.57 (d, 9.8 Hz, δC 130.2) and 6.32 (d, 9.8, δC 122.3), in addition to the absence of the 
methylene group signal of compound 1, indicated the formation of a pyran ring between C4-C3` 
of compound 1.  
O
O
O
2
1`
4`
 
Figure 3.22: Some important HMBC correlations of compound 3 (from H to C) 
The structural modification was supported by the chemical shift of the first double bond in the 
geranyl group, and the HMBC correlation of H-3/C-2, C-4, C-10, C-1` and H-4/C-5, C-9, C-2 
(among others, Figure 3.21). The above data confirmed the structure of compound 3 as 2-methyl-
2-[4`-methyl-3`-pentenyl]-2H-chromen-6-[1-propenoic acid methyl ester], and given the trivial 
name psorticane B (Table 3.4). 
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3.4.2 Compound 5 
Compound 5 has molecular formula C20H26O3, and showed very similar NMR spectra of 
compound 1 (Figure 3.18)—the only difference is the chemical shift C9 to 172.8 (168.2 
compound 1) which indicate free carboxylic group. The hydroxylated carbon was located at C4 
as deduced from the HMBC correlation of H1`/C4, C5, C6; and H7/C6, C2, C1, additionally, the 
methoxyl proton showed HMBC with C4. Other 2D NMR spectra confirmed the structure of 
compound 5 as (Figure 3.18), and given the trivial name psorticane C (Table 3.4). 
3.4.6 Compound 6 
Compound 6 has molecular formula of C20H26O4 from HRMS. The NMR spectra was very 
similar to compound 1 (Figure 3.19), except for the existence of extra hydroxyl group attached to 
the benzene ring which confirmed from the presence of only m-coupled two aromatic proton 
signals at δH 6.84 (br. s), and 6.97 (br. s) both protons located at C2, C6 positions of the 
coumaric side chain, which confirmed by the HMBC correlations between H7/C1, C2, C6 and 
H1`/C5, C4, C6. Other 2D NMR spectra confirmed the structure of 6 as (Figure 3.19) and given 
the trivial name psorticane D (Table 3.4). 
3.4.7 Psilalste, Psoralen and 6-Hydroxy Coumarin 
Additionally, three known compounds were isolated from the same extract and identified as 
psilalate (2)111, psoralen (4) and 6-hydroxy coumarin (7).112 To the best of our knowledge, 
compound 2 is reported for the second time from a natural source and both compounds 2 and 7 
were isolated for the first time from Psoralea genus. 
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Table 3.4: 1H (400 MHz) and 13C (100 MHz) of compounds 1, 2, 3, 5 and 6 
No Psorticane A (1) Psilalate (2) Psorticane B (3) Psorticane C (5) Psorticane D (6) 
1 127.6 s  126.6 s    127.1 s  126.5 s  
2 156.8 s  135.7 d 7.69* 79.5 s  112.2 d 6.97 br s 129.3 d 7.34 br s 
3 116.1 d 6.8 d 120.5 s  130.2 d 5.57 d, 9.8 144.4 s  130.8 s  
4 127.7 d 7.26* 163.1 s  122.3 d 6.32 d, 9.8 144.5 s  159.7 s  
5 126.9 s  118.6 d 7.02 d, 8.8 126.1 d 7.11 d, 2.0 127.6 s  110.3 d 6.82 d, 8.4 
6 130.1 d 7.26* 133.9 d 7.71 dd, 2.0, 8.8 126.9 s  122.8 d 6.84 br s 128.1 d 7.36 dd, 8.4, 1.6 
7 145.2 d 7.60 d, 16.0 142.6 d 7.64 d, 16.0 129.5 d 7.26 dd, 8.5, 2.0 145.1 d 7.54 d 147.2 d 7.71 d 15.6 
8 114.6 d 6.26 d 16.0 116.9 d 6.35 d, 16.0 116.5 d 6.73 d, 8.5 115.4 d 6.23 d 114.3 d 6.28 d 15.6 
9 168.2 s  167.3 s  155.5 s  167.9 s  172.8 s  
10     121.1 s      
11     144.5 d 7.57 d, 16.0     
12     114.9 d 6.25 d, 16.0     
13     167.8 s      
1` 29.3 d 3.34 d 196.3 d 9.91 s 41.5 t 1.65 m 29.6 t 3.35 d 28.1 t 3.30 d, 7.0 
2` 121.1 d 5.30 br t   22.7 t 2.11 m 121.1 d 5.28 t 121.5 d 5.28 br t, 7.0 
3` 138.8 s    123.8 d 5.06 t, 6.4 139.4 d  136.9 s  
4` 39.6 t 2.08 m   131.9 s  39.7 t 2.08* 39.8 t 2.06, m 
5` 26.4 t 2.08 m   25.6 q 1.63 s 26.3 t 2.09* 26.7 t 3.09 m 
6` 123.8 t 5.06 br t   17.6 q 1.54 s 123.7 d 5.04 t 124.2 d 5.10 t 6.0 
7` 131.9 s    26.9 q 1.38 s 132.3 s  131.5 s  
8` 25.6 q 1.66 s     25.7 q 1.67 s 25.7 q 1.66 s 
9` 17.7 q 1.58 s     17.7 q 1.61 s 17.7 q 17.7 s 
10` 16.2 q 1.74 s     16.2 q 1.75 s 16.1 q 1.69 s 
OMe 51.6 q 3.77 s 51.8 q 3.79 s 51.6 q 3.77 s 51.6 q 3.77 s 55.5 q 3.85 s 
2-OH           
3-OH           
4-OH           
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3.5 Discussion 
Chromatographic separation of the active extract from P. fruticans using different techniques, 
including semi-prep HPLC yielded seven pure compounds, viz. psorticane A (1), psilalate (2), 
psorticane B (3), psoralen (4), psorticane C (5), psorticane D (6) and 6-hydroxycoumarine (7). 
Psorticanes A-D are new compounds reported for the first time from a natural source. The 
identification of the isolated compounds was effectively completed using extensive analysis of 
the NMR spectroscopic data. Different metabolites have been reported from Psoralea genus, 
including coumarins, furanocoumarins, flavonoids, meroterpenoids and comestanes (see section 
3.2.2 of this chapter).  
The isolation of coumaric acid derivatives have not been reported so far from this genus. It is of 
interest to indicate that C-geranyl derivatives of phenolic acids and especially coumaric acids are 
rare metabolites and have been described from Chrysothamnus pulchellus.113 The isolation of the 
C-geranyl derivatives of coumaric acid adds a new dimension to the secondary metabolites 
profile of Psoralea genus. However, prenylated derivatives have been isolated from the genus, 
but the geranyl derivatives are reported for the first time in this study. 
3.3 Biological Evaluation of the Isolated Compounds 
3.3.1 Determination of Antibacterial Activity by TLC Bioautography 
The pure compounds were diluted in methanol and spotted onto TLC plates. The plates were 
thoroughly sprayed with a dense culture of S. mutans, incubated for 24 hours in a humid 
atmosphere to allow growth of bacteria. After the incubation period, one of the plates was 
sprayed with INT and incubated for 2 hours.56,57 The other plate was developed with 3% 
MeOH:DCM and sprayed with vanillin acid and heated. 
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3.3.2 Determination of MIC and MMC of the Pure Compounds 
The methodology is essentially as described before in Chapter 2. Different concentrations of the 
compound samples were tested to obtain the MIC values using serial dilutions (100, 50, 25, 12.5 
and 6.25 µg/ml).58,59 
3.3.3 Determination of Biofilm Formation 
The same methodology used for extracts was applied for the pure compounds, except that the 
slides were covered with compounds and left to dry completely. Then 50µl of fresh medium and 
50 µl of bacteria were add and incubated at 37°C for 24 hours in a humid atmosphere to allow 
growth of bacteria.60 Neomycin was used as a positive control and untreated cells as a control. 
After 24 hours, the slides were rinsed with sterile PBS and fixation performed as described in 
Chapter 2. 
3.3.4 Cell Culture 
KMST-6 fibroblasts, a normal human cell line, were cultured in DMEM (Dulbecco’s Modified 
Eagles medium), supplemented with (10% v/v) foetal bovine serum and antibiotic (1% v/v). 
Cryogenic vials containing the cells were taken from the -150°C freezer and slowly thawed to 
37ᵒC. The cells were plated into 25-cm2 flasks and cultured in a humidified CO2 incubator (5% 
CO2:air) at 37ᵒC until confluency was reached. The culture medium was replaced every 48 hours. 
3.3.5 Subculturing of Cells 
After the cells were grown to 90% confluency, the culture medium was discarded and cells 
washed with 5 ml phosphate buffered saline solution and 3 ml of pre-warmed trypsin was added 
to detach the cells. The flasks were incubated for 3 minutes at 37°C until cells detached from the 
bottom of flasks. About 2 ml of growth medium was added to deactivate the action of trypsin and 
the mixtures were transferred into sterile 50-ml conical tubes and centrifuged at 2500 rpm for 3 
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minutes using a Sorvall TC6 centrifuge. After centrifugation, fresh growth medium was added to 
the cell pellets after discarding the supernatant. The cell pellets were either re-suspended in 
growth medium or growth medium containing 10% DMSO depending on whether the cells were 
going to be seeded into new flasks or whether the cells were going to be stored at -150°C. 
3.3.6 Storage of Cells 
After trypsinization, the cell pellet was re-suspended in growth medium containing 10% DMSO. 
The suspension was transferred to labelled cryogenic vials and stored at -150°C.  
3.3.7 Cell Counting 
Cell counts were performed as per the manufacturer‘s instructions using a CountessTM automated 
cell counter (Invitrogen).  
3.3.8 Preparation of Stock Solutions of the Extract and Compounds 
The extract and compounds were weighed first and dissolved in DMSO. The final concentration 
of DMSO in this step did not exceed 5%. After that the extract and compounds were diluted in 
growth medium to reach a concentration of 1000 µg/ml. The DMSO final concentration after 
dilution was 1%. 
3.3.9 WST-1 Cell Proliferation Assay 
The growth inhibitory effects of the methanolic extract of P. fruticans and some of the isolated 
compounds were evaluated using the tetrazolium salt, i.e., the WST-1 colourimetric assay, as 
recommended by the manufacture (Roche Diagnostics GmbH, Mannheim, Germany).114 The 
cells were cultured to 90% confluence and trypsinized as described before. The cells were seeded 
in a 96-well culture plates at a density of 5 x 104 cells/100 μl per well. The plates were incubated 
at 37°C in a humidified CO2 incubator for 24 hours to allow the cells to attach to the bottom of 
the plate. A dilution series was made of the extract with increasing concentrations (62.5, 125, 
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250, 500 μg/ml) and the concentrations of isolated compounds were (25, 50, 75 and 100 µg/ml). 
Then the culture medium was removed and the cells were treated. As a positive control, the cells 
were treated with 6% DMSO, a known inducer of apoptotic cell death and since DMSO is 
known to be toxic to cells; 115 an additional control was set up to evaluate its toxicity. The cells 
were therefore also treated with 1% DMSO. Untreated cells were used as a negative control. All 
treatments were done in triplicate. After 24 hours, 10 μl WST-1 reagent was added to the wells, 
and the plates were incubated at 37°C for another four hours. The optical density/absorbance of 
the wells was determined using a BMG Labtech POLARstar Omega microplate reader and the 
plates were read at 430 nm, and 630 nm was used as a reference wavelength. The percentage of 
cell viability was calculated by comparing the absorbance of the test samples with the 
absorbance of the control (untreated) samples using the following calculation: 
% cell viability = Sample absorbance − cell free sample blankcontrol absorbance  X 100 
 
3.3.10 Results 
3.3.10.1 Qualitative Screening Using TLC Bioautography 
The active compounds showed inhibition zones on the plate. The place of growth inhibition on 
the plate are shown via clear or creamy-white spots against the intensely coloured background 
indicative of bacterial growth (Figures 3.23 and 3.24). Zones of inhibition by compounds on the 
plate were visualized using the P-iodonitrotetrazolium violet (INT) detection system.56,61 
3.3.10.2 Minimum Inhibitory (MIC) and Microbicidal Concentration (MMC) 
Of the six tested compounds six were active and one compound showed no activity. Compound 3 
was not active as confirmed by the bacterial growth in the five tested concentrations with MIC 
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and MMC values in excess of 100µg/ml. Compounds 1 and 5 were the most active as they 
inhibited the growth at 6.25 µg/ml with MMC 12.5 µg/ml. Compound 4 was the second most 
active exhibiting an MIC of 12.5 µg/ml and MMC of 25 µg/ml. Compound 6 was inhibited 
bacterial growth at 50 µg/ml with an MMC of 100 µg/ml whereas compound 2 exhibit growth 
inhibition at 100 µg/ml as illustrated in Table 3.5.  
 
 
Spot number 5 is identical to spot number 6. 
Figure 3.23: TLC plates of the pure compounds sprayed with bacteria (A) and vanillin acid (B) 
3.3.10.3 Streptococcus Mutans Biofilm Formation 
The cells treated with the compounds showed a reduction in cell numbers and no development of 
a biofilm. Compound 1 showed no development of S. mutans on the glass slide and few bacteria 
that attached to the slide. Compounds 3 and 5 showed that cells adhered to each other. The other 
compounds showed no biofilm development (Figure 3.25).  
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The pink colour indicates that the bacteria are still live and the yellow colour indicates dead bacteria. 
Figure 3.24: The minimum inhibitory concentration 96-well plates for the compounds 
3.3.10.4 Cytotoxic Effects of the Total Extract of Psoralea fruticans 
Non-tumorigenic immortalized normal human human diploid fibroblasts cells (KMST-6)45 were 
treated for 24 hours with the total methanolic extract of P. fruticans as described before.  
 
 
 
 
CHAPTER 3 | 3.3.10.4 Cytotoxic Effects of the Total Extract of Psoralea fruticans 
76 
   
Compound 1 Compound 2 Compound 3 
   
Compound 4 Compound 5 Compound 6 
  
Control Positive control 
Figure 3.25: Streptococcus mutans biofilm developed on glass slides and treated with the compounds  
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Table 3.5: MIC, MMC and IC50 values of the crude extract and isolated compounds of Psoralea fruticans 
Sample MIC (µg/ml) MMC (µg/ml) IC50 (µg/ml) 
Total extract 31.25 62.25 71 
Compound 1 6.25 12.5 <25 
Compound 2 50 100 >100 
Compound 3 >100 >100 >100 
Compound 4 12.5 25 >100 
Compound 5 6.25 12.5 44 
Compound 6 50 100 >100 
 
The cell viability following treatment was determined using the WST-1 assay.68 The viability of 
KMST-6 was unaffected at 62.5 μg/ml, while no viability was observed at the highest dose of 
125 μg/ml. with an IC50 value of 71 µg/ml (Table 3.5). 
3.3.10.5 Cytotoxic Effects of the Isolated Compounds of Psoralea fruticans 
Six compounds were selected to assess their cytotoxic effects of KMST-6 normal human 
fobroblasts. The cells were treated for 24 hours with the pure compounds as described before and 
cell viability were assessed using WST-1 assay.114 The IC50 values for these compounds were 
determined (Table 3.5). Compounds 2, 3, 4, and 6 were inactive in the cytotoxic assay with IC50 
valued >100µg/ml. Compound 5 was active with IC50 value of 44 µg/ml and compound 1 was the 
most active compound in cytotoxic assay with IC50 <25 µg/ml (Table 3.5, Figure 3.26). Figure 
3.27 shows the effect of the total methanolic extract of P. fruticans on KMST-6 cell viability. 
3.3.11 Conclusion  
TLC bioautography plate with isolation compounds showed a clear inhibition growth spots. 
Compounds 1, 4, 5, and 6 showed creamy-white inhibition zones. Quantification of the 
antibacterial activity of isolated compounds was carried out using serial plate microdilution.53  
 
 
 
 
CHAPTER 3 | 3.3.11 Conclusion 
78 
  
  
  
 
Figure 3.26: Absorbance profiles for the MIC of the compounds 
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Figure 3.27: Effect of the total methanolic extract of P. fruticans on KMST-6 cell viability 
Compounds 1 and 5 were the most active in inhibiting the growth of S. mutans at 6.25 µg/ml 
with MMC of 12.5 µg/ml. Compound 4 also inhibited bacterial growth at 12.5 µg/ml with MMC 
of 25 µg/ml while compound 6 did so at 50 µg/ml with MMC of 100 µg/ml. S. mutans biofilm 
development determined using glass slides treated with the isolate compounds showed a decrease 
in cell number. The cytotoxic assay was carried out for the crude methanol extract and six 
isolated compounds to assess if the extract and compounds exerted toxic effects on normal 
KMST-6 human fibroblasts. The cells viability was assessed using the WST-1 assay.  
The total crude extract were not toxic which showed IC50 value of 71 µg/ml. Compounds 1 and 5 
were found to be the most active with IC50 values <25 and 44 µg/ml, respectively. Compound 1 
had toxic effect on the human cell line and compound 5 showed some cytotoxic effect, while the 
all other compounds were regarded as safe in human cell line, i.e., inactive in cytotoxic assay 
with IC50>100µg/ml. Compound 4 which is psoralen was considered to be inactive as measured 
by the cytotoxic assay as previously reported.36 According to another study,104 psoralen showed 
to have cytotoxic effect on stomach cancer cell line with IC50 value of 53 µg/ml in SNU-1 and 
203 µg/ml in SNU-16.  
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CHAPTER 4 
CONCLUSION 
Many South African plants are now being investigated for potential antimicrobial activities. In 
this study, about 32 South African medicinal plants were collected from the Cape Flats region 
and tested against S. mutans. The plants were extracted with methanol and thin layer 
chromatography (TLC) used as a screening method for the detection of antimicrobial activity of 
the compounds.57,116 The 32 plant extracts were spotted on TlC plates and developed in 3% 
MeOH:DCM. Then the plates were sprayed with S. mutans and incubated for 24 hours in a 
humid atmosphere to allow the growth of bacteria. Zones of inhibition by the compounds on the 
plate was envisaged using INT56. TLC plates showed eight extracts that exhibited antibacterial 
activity with clear inhibition zones.  
The microdilution assay was used to investigate the inhibition of bacterial growth.53 Eight plants 
were active at 500 µg/ml concentration, namely, Salvia africana caerulea, Psoralea fruticans, S. 
africana lutea eloca, Acacia karro, Helichrysum cymosum, Psoralea pinnata, Helichrysum 
zeyheri and Castanea sativa) and three were active at 100 µg/ml, namely, Psoralea fruticans, 
Psoralea pinnata and Helichrysum cymosum). The minimum inhibitory concentration (MIC) and 
minimum microbicidal concentration (MMC) were determined for the eight active extracts: 
Psoralea fruticans and Psoralea pinnata yielded the most active extracts which inhibit the 
growth of bacteria at MIC 31.25 µg/ml with MMC of 62.5 µg/ml. S. africana lutea eloca, S. 
Africa acrulea and Acacia karroo inhibited bacterial growth at MIC 62.5 µg/ml and MMC of 
125 µg/ml. Helichrysum zeyheri, Helichrysum cymosum and Castanea sativa inhibited the 
growth of bacteria at MIC 125 µg/ml and MMC 250 µg/ml. 
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Psorolea fruticans was selected for phytochemical studies to isolate the active constituents 
because of its antibacterial activity at lower concentrations and according to TLC plate which 
showed that Psoralea fruticans have potential bioactive compounds. This finding is noteworthy 
because there are few chemical or biological studies published on Psoralea fruticans. 
Chromatographic separation of the active extract from P. fruticans using different techniques, 
including semi-prep HPLC yielded seven pure compounds, viz., psorticane A (1), psilalate (2), 
psorticane B (3), psoralen (4), psorticane C (5), psorticane D (6) and 6-hydroxycoumarine (7); 
psorticanes A-D are new compounds reported for the first time from this natural source. The 
identification of the isolated compounds was effectively completed using extensive NMR 
spectroscopy.  
Different metabolites have been reported from Psoralea genus, including coumarins 
furanocoumarins, flavonoids, meroterpenoids and comestanes. The isolation of coumaric acid 
derivatives have not hitherto been reported for this genus. It is of thus of interest to indicate that 
C-geranyl derivatives of phenolic acids and especially coumaric acids are rare metabolites and 
have been described from Chrysothamnus pulchellus.113 The isolation of the C-geranyl 
derivatives of coumaric acid add a new dimension to the secondary metabolites profile of 
Psoralea genus. However, prenylated derivatives have been isolated from the genus, but the 
geranyl derivatives are reported for the first time in this study. 
Seven compounds were selected to antibacterial and cytotoxic evaluation. The MIC of pure 
compounds were determined using the serial plate microdilution assay.53,59 The MIC is 
demarcated as the lowest concentration that inhibited the growth of the bacteria. Six compounds 
inhibited bacterial growth. One compound was not active at the tested concentration. Compounds 
1 and 5 were the most active compounds which inhibited the growth of bacteria at MIC 6.25 
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µg/ml with MMC of 12.5 µg/ml and compound 4 next at MIC 12.5 µg/ml with MMC of 25 
µg/ml. Compounds 2 and 6 inhibited bacterial growth at MIC 50 µg/ml with MMC of 100 µg/ml.  
An improved method was used for investigating the effect of the active extracts and the purified 
compounds from Psoralea fruticans on S. mutans biofilm information.117 S. mutans biofilm 
development was measured on glass slides for 24 hours in a humid atmosphere. After incubation, 
glass slides were treated with the crude extracts of the eight active plants and isolated 
compoonds.60 Some extracts showed biofilm development, including Acacia green, Salvia 
Africana lutea, Psoralea pinnata, Helichrysum cymosum, Helichrysum zeyheri and Castania 
sativa. Two plants showed no development on biofilm (Salvia africana careulea and Psoralea 
fruticans). The compounds were not preventing S. mutans to attach to the glass, but showed 
reduction in cell numbers and no biofilm development.  
Psoralea fruticans extract and seven compounds were selected for cytotoxic evaluation on 
KMST-6 human fibroblasts. The cell viability was determined using WST-1 assay.114 The results 
showed that the methanol extract of Psoralea fruticans is safe on KMST-6 cells with an IC50 
value of 71 µg/ml. Five of the test compounds were found to be non-toxic to KMST-6 cells (IC50 
value >100 µg/ml), while compounds 1 and 5 showed some toxic effect on KMST-6 cells (IC50 
value <25 µg/ml and 44 µg/ml, respectively). These results may have significant implications in 
the treatment of oral disease caused by cariogenic bacteria, including S. mutans. 
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